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Abstract: The first gene therapy clinical trials were started nearly 30 years ago, but the 
field only now seems to be on the verge of widespread adoption. Safe and efficient gene 
delivery, however, is still a major obstacle and is often described as “the Achilles’ heel of 
gene therapy.” Adenovirus (Ad) is the most common viral vector in gene therapy clinical 
trial. Adenovirus fiber and capsid proteins, however, mediate an immunogenic response 
and relies on interaction of the virus with the coxsackie adenovirus receptor (CAR), 
which limits the ability of the virus to deliver genes into CAR-negative cells such as 
cancer cells. Our goal was to develop a hybrid vector that overcomes Ad drawbacks as 
well as understand how our hybrid vector compare to the native virus in intracellular 
trafficking. A fiberless adenovirus (FlAd) was used with a replacement for the removed 
fiber protein by poly-L-lysine copolymer grafted polyethylene glycol (PLL-g-PEG). A 
copolymer library was synthesized using varying molecular weights of PLL and PEG 
with different degrees of grafting. Hybrid vectors were formed by electrostatically 
associating PLL-g-PEG with FlAd at different ratios, where “design of experiments” was 
used to optimize the approach. Hybrid vectors were evaluated by their ability to infect 
both CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells. To guide further 
development of the hybrid vector, we investigated the mechanisms of intracellular 
trafficking by measuring transduction efficiency and cellular uptake in the presence of a 
panel of drug inhibitors of various cellular pathways. PLL-g-PEG-FlAd hybrid vectors 
were able to transduce CAR-positive HEK 293 cells and CAR-negative NIH 3T3 cells 
with a 3.5- and 10.2-fold increase compared to unmodified FlAd. Addition of the PLL-g-
PEG copolymer restored 85% of the infectivity of Ad in HEK 293 cells that was lost as a 
result of removing the fiber. In addition, hybrid vector was non-cytotoxic on both cell 
types and showed good serum stability up to 40%. The production of inflammatory 
cytokines IL-6 and TNFα was also reduced by 70% and 50%, respectively. The removal 
of the fibers besides the surface modification with PLL-g-PEG copolymer have modified 
the intracellular trafficking of the hybrid vector to affect the efficiency of the expression 
of the targeted gene. This stepwise transition from viral to non-viral vectors will lead to 
novel vectors that are both safe and highly efficient. 
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GENE THERAPY FROM CONCEPT TO MARKET: CURRENT TOOLS AND LIMITATIONS 
 
The human genome contains ~20,000–25,000 genes encoding different proteins that drive 
every biological process necessary for life and death [1]. The Human Genome Project, an 
international scientific research project, advanced the understanding of the genetic code 
embedded in the DNA by identifying the genetic makeup and mapping the human DNA [2, 3]. 
Any abnormalities in the genome can lead to genetic malfunctions that are translated to altered 
proteins which cause the diseases. Gene therapy is an experimental technique that delivers genes 
into a patient’s cells to either replace a mutated gene with a healthy copy of the gene, or 
inactivates, “knocks out,” a mutated gene that is functioning improperly, or introduces a new 
gene into the body to help fight a disease. The FDA defines gene therapy as products that mediate 
their effects by transcription and/or translation of transferred genetic material, and/or by 
integrating into the host genome and that are administered as nucleic acids, plasmids, viruses, or 
genetically engineered microorganisms [4].  
1.1 TYPES OF GENE THERAPY 
Depending upon the type of disease, the therapeutic gene, and the gene delivery vector, 
gene therapy can be in vivo or ex vivo (Figure 1.1). An in vivo gene therapy involves the 
administration of the therapeutic gene into the patient with the help of a delivery system that is 
used for all patients with a similar diagnosis. In vivo gene therapy, however, usually causes  
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a wide distribution of vectors to undesired tissues and leads to complications [5]. In vivo gene 
therapy also requires vectors that can maneuver through the patient’s body to deliver the 
therapeutic gene to a specific tissue. Gene delivery vectors have to overcome tissue matrices, 
avoid enzymatic degradation, and evade inactivation by the immune system to effectively transfer 
the gene into the desired cell [6]. Ex vivo gene therapy, in contrast, involves the administration of 
treated cells originally extracted from a patient. The cells then introduce the desired therapeutic 
change in the body of the patient. This method is invasive and requires patient-specific tailoring, 
hence incurring high manufacturing costs and quality-control difficulties. Having all these 




Figure 1.1: Schematic diagram of in vivo and ex vivo gene therapy. In vivo gene therapy involves 
the administration of the gene delivery vector that contains the therapeutic gene. Ex vivo gene 
therapy involves the use of cells extracted from the patient to be engineered in the lab and 
delivered back to the patient to provide the desired therapeutic change. 
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1.2 FIRST STEPS OF GENE THERAPY 
Gene therapy was conceptualized in 1970 when Stanfield Rogers proposed the use of 
"good" DNA to replace defective DNA as a treatment for inherited diseases [7]. Despite the idea 
having been introduced, the first gene therapy procedure did not occur until 1990 on patients 
suffering from ADA-SCID, or “Bubble Boy Disease”. Adenosine deaminase (ADA) deficiency is 
an inherited disorder that damages the immune system and causes severe combined 
immunodeficiency (SCID) [8, 9].   
Two ADA-SCID patients were treated with white blood cells taken from their own blood 
and modified ex vivo to express the normal gene. The introduction of the correct genes showed 
vast improvement to the point of having normal immune systems [10]. One patient, Ashanti 
DeSilva, exhibited a good response, whereas the response in the second patient was far less 
(Blaese et al., 1995). However, there was a debate about the effect of DeSilva’s gene therapy as 
she still received simultaneously enzyme replacement therapy alongside with the gene therapy. 
This gene therapy clinical trial was not curative, but an effective treatment that did open the door 
for further successful trials that have cured patients of several diseases. Several gene therapy 
clinical trials followed, but in some studies, patients who received the treatment developed 
leukemia which raised a safety concern [11]. Gene therapy thrived until the tragic death of Jesse 
Gelsinger [12]. In 1999, the worst-case scenario for gene therapy happened, when 18-year old 
Jesse Gelsinger took part in a gene therapy clinical trial at the University of Pennsylvania. He 
suffered from a deficiency of ornithine transcarbamylase (OTC), a liver enzyme that is required 
for the removal of excess nitrogen from amino acids and proteins. Gelsinger's death was 
attributed to his body's inflammatory immune response after a high dose of adenoviral vector 
injection [13]. In a flash, the field of gene therapy collapsed, and research became more oriented 
to achieve an efficacious, yet safe gene delivery system. 
4 
1.3 CURRENT POSITION OF GENE THERAPY 
Several milestones have marked the field of gene therapy as shown in Figure 1.2. To 
date, a steady-state increase in the number of gene therapy clinical trials has been achieved with 
more than 2600 clinical trials completed.  
 
Figure 1.2: Milestones in gene therapy. 
Gene therapy extended from treating inherited diseases such as muscular dystrophy [14] 
and cystic fibrosis [15] to treating acquired diseases such as cancer [16], cardiovascular diseases 
[17], Parkinson’s disease, and Alzheimer’s disease [18-21]. The ability of gene therapy to treat a 
wide variety of diseases is owed to the fact that gene therapy targets the underlying cause of the 
disease through long-lasting production of the desired therapeutic protein at the fixed area of the 
defect [22]. Thus, gene therapy provides a one-time treatment option for a complete cure as well 
as disease prevention. To date, the majority (76.1%) of gene therapy clinical trials have addressed 
cancer (65.0%), but the greatest success was for the inherited monogenic diseases (11.1%). 
Figure 1.3 shows a distribution of the indications addressed by gene therapy clinical trials [23].  
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Figure 1.3: Indications addressed by gene therapy clinical trials. 
Over the last two decades, gene therapy has made tremendous progress as it has moved to 
the market as shown in Figure 1.4. The first commercial gene therapy product was approved by 
China in 2004. Gendicine™ is an adenoviral vector, wherein the E1 gene is replaced with a 
human p53 cDNA, to treat head and neck squamous cell carcinoma [24]. Soon after approval, 
debates were raised against the efficacy of the treatment [25]. Despite the debates, China 
approved Oncorine™ two years later to be used in combination with chemotherapy for the 
treatment of late-stage refractory nasopharyngeal cancer. In 2004, Ark therapeutics in Europe 
manufactured Cerepro® to enter clinical trials as an adenoviral vector for the treatment of 
malignant brain tumors [26]. Cerepro® became the first adenoviral vector that has completed a 
phase III clinical trial. The first commercial gene therapy product (Glybera), was approved by the 
European Medicines Agency (EMA) in 2012 [26]. Glybera is an adeno-associated viral vector 
engineered to express lipoprotein lipase in the muscle tissue for the treatment of severe 
lipoprotein lipase deficiency (LPLD). However, only one or two people in every one million are 




















withdrawn from the market due to low patient demand. Another retrovirus-based drug, 
StrimvelisTM, was approved later in 2016 to treat, ADA-SCID, or Bubble Boy Syndrome. In 
August 2017, the USA market launched the FDA approved KymriahTM as the first CAR-T cell 
therapy product to treat acute lymphoblastic leukemia[27] . Soon after, Yescarta™ and Luxturna 
were granted by the FDA in October and December, respectively. YescartaTM is another 
retrovirus-based CAR-T cell immunotherapy[28] , while Luxturna is the first adeno-associated 
virus (AAV) based gene delivery product to treat X-linked inherited retinal dystrophy that causes 
night blindness [29]. Finally, ZolgensmaTM is the most recent gene therapy approved by the FDA 
on May 24, 2019 [30]. ZolgensmaTM is an AAV based gene delivery product intended for use in 
children less than 2 years old with spinal muscular atrophy (SMA). 
 
Figure 3.4: Gene therapy drugs in the pharmaceutical market and a timeline of their approval. 
 
Gene therapy is a rapidly growing field, where scientists have only scratched the surface 
of its potential. As mentioned elsewhere, the more that is discovered about how to optimize gene 
delivery vectors, the closer this field gets to delivering wide scale solutions to modern medicine 
[31]. The future of gene therapy moves toward engineering safer and more efficient vectors, 
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combining multiple existing strategies such as viral vectors with genetic and chemical 
engineering techniques. To achieve these goals, understanding of the physicochemical 
characteristics as well as the trafficking of the designed gene delivery are necessary. 
1.4 GENE THERAPY CHALLENGES 
Ethical concepts 
 
All cells in the human are potential targets for gene therapy. However, gene therapy can 
be divided into two major categories depending on the target cell: somatic cell gene therapy 
(most cells of the body) or germline gene therapy (eggs or sperm). To date, somatic cell gene 
therapy to treat different diseases undergoes acceptable clinical trials. However, ethical concerns 
limit the feasibility of germline gene therapy as the genetic change can be used for trait 
enhancement of off springs. There is a public debate from the fields of biology, government, law, 
medicine, philosophy, politics, and religion, each bringing different views to the discussion.  
Extracellular and Intracellular barriers 
 
Regardless of the method of its administration in vivo (e.g., by inhalation, intramuscular 
injection, intravascular injection, etc), the gene delivery vector will face extracellular and 
intracellular barriers before it delivers its cargo inside the target cell nucleus.  
Extracellular barriers 
Multiple barriers exist within the extracellular milieu, which can result in rapid clearance 
and/or degradation of the vector before it ever reaches the target cells. These barriers include 
enzymatic degradation and serum protein interaction. Intravenously delivered naked DNA has a 
very short half-life within serum (1.2–21 minutes) [32]. This is believed to be the result of both 
endo- and exo-nuclease activity in the plasma. Different strategies have been adopted to protect 
the DNA from enzymatic degradation like coating with cationic lipids and polymers as well as 
coating with a hydrophilic polymer like polyethylene glycol (PEG) to enhance the stability of 
DNA [33]. After evading nucleases, the gene delivery vector must resist undesired interactions 
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with serum proteins. Negatively charged serum proteins form aggregates with cationic vectors 
which results in their rapid removal from the circulation.  
Gene delivery vectors also encounter different blood cells, including erythrocytes, 
leukocytes, macrophages, and platelets. Cells have a negative surface charge which allows for 
electrostatic interactions with cationic vectors [34]. Interaction with erythrocytes leads to 
haemagglutination and it speeds up the removal of the vectors via the reticuloendothelial system 
(RES). The gene delivery vector is also engulfed with macrophages before it can transfect any 
other cell type [35].  
Another extracellular barrier to consider is the activation of both the innate and adaptive 
immune responses. After systemic administration of either viral or non-viral vectors, the body 
develops an inflammatory response leading to the release of multiple cytokines that clears the 
vector from the circulation [36]. The presence of preexisting neutralizing antibodies (NAbs) in 
the human population from earlier natural infections also reduces the efficacy of viral vectors 
[37]. A common approach to reducing both innate and adaptive immune responses to viral 
vectors is to coat the virus surface with PEG. Coating with PEG reduces the clearance of the virus 
from circulation and hence improves the efficiency of the treatment [38, 39] 
Intracellular barriers 
Once the gene delivery vehicle has reached a cell, it then encounters multiple intracellular 
barriers. First, the vector must pass the plasma membrane and be endocytosed. Naked DNA does 
not associate efficiently with the plasma membrane due to the negative charge density on both the 
DNA and the cell surface. Different delivery vectors have been developed to help circumvent this 
problem.  
Gene delivery vectors then moves through the cytoplasm to reach the nucleus, where they 
have to escape degradation by the endolysosomal network and the harsh pH conditions inside the 
lysosomes. There are several mechanisms employed to increase the likelihood of endosomal 
escape including membrane fusion, i.e. proton-sponge effect and incorporation of fusogenic and 
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pore-forming peptides. Lipoplexes escape the endosome through a fusion of the liposome with 
the endosomal membrane [40], while the proton sponge effect helps polyplexes containing 
polyethyleneimine (PEI) to escape endosomes [41].  
Once the vector has successfully been released, it moves through the cytoplasm to reach 
where gene expression occurs. This step represents another significant barrier to gene delivery. 
First, the cytoplasm contains nucleases that will degrade free DNA, whether this DNA is 
delivered naked or dissociated from the vector before nuclear entry [6]. Additionally, the 
cytoplasm itself poses a diffusional barrier, being a viscous environment crowded with molecules, 
which results in decreased mobility of macromolecules [42]. Thus, the vectors must translocate 
through the cytoplasm by binding to the microtubule network to release the DNA near the 
nucleus.   
The size of the DNA is a determining factor for nuclear transport through the nuclear 
membrane. Only molecules less than 9 nm in diameter successfully diffuse through the 
membrane, while larger molecules need active transport by nuclear localization signal peptides 
[43]. Viral vectors have inherent properties that allow them to utilize the nuclear import facilities 
of the cell. In contrast, non-viral vectors like lipids and polymers do not have that ability and they 
rely upon cell division. During the cellular division, the nuclear membrane of the cell breaks 
down thereby giving a chance to the therapeutic gene for nuclear entry. Performing transfection 
studies immediately before cell division increases the gene expression by 30 to 500-fold 
compared to the transfection studies at the beginning of the cell cycle [44]. 
Although complex formation between DNA and gene delivery vectors protects the gene 
from degradative enzymes inside the cell, this complexation prevents transcriptional protein 
binding to therapeutic genes [45]. For gene expression inside the cell, binding of a therapeutic 
gene with transcriptional proteins is the initial step. Therefore, the gene delivery vector should be 
designed to incorporate the balance between enzymatic degradation and gene release. Earlier 
studies have shown that the addition of PEG or reduction of polymer molecular mass can reduce 
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the positive charge of cationic polymer and thereby reducing the binding strength and increasing 
gene expression [46]. Finally, even though the intracellular trafficking poses as a significant 
barrier to gene transfer, many techniques for overcoming this problem are being revealed. 
 
Figure 4.5: Schematic diagram of barriers facing gene delivery vector. Extracellular barriers are 
encountered after systemic administration of the vector, including interaction with serum proteins 
and erythrocytes, innate immune response, and adaptive immune response. Intracellular barriers 
start by facing the cell membrane where the vectors must bind to cellular components that induce 
endocytosis. After entering the cell, the vector must escape the endosome and release the genetic 
material close to the nucleus. The genetic material is then taken up by the nucleus via the nuclear 
pore. 
1.5 GENE DELIVERY VECTORS 
For successful gene therapy, a safe and efficient delivery vehicle that can carry a gene to 
the desired cell has to be developed. Ideally, gene delivery vectors have to selectively deliver the 
genetic material to the target cells, be immunologically inert, and have a large capacity to carry 
large-sized genetic materials. Besides, gene delivery vectors should not interfere with the genes in 
the host cell since unsought gene integration to the host genome might result in mutagenesis. As 
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mention before, the gene delivery vector must overcome all the extracellular and intracellular 
barriers before delivering its cargo inside the nucleus to achieve the required therapeutic action. 
Developing an ideal gene delivery vector meeting all these conditions is very difficult and is 
considered the ‘Achilles heel’ of gene therapy [18].  
Gene delivery vectors are generally classified into viral and non-viral vectors. A variety 
of different vectors and delivery techniques has been applied in gene therapy trials as shown in 
Figure 1.6.  Although non-viral approaches are becoming more common, viral vectors are still far 
more popular, having been used in approximately two‐thirds of the trials performed to date [23]. 
 
Figure 5.6: Vectors used in gene therapy clinical trials 
Viral gene delivery vectors 
Viral gene delivery systems are based on the natural ability of the virus to hijack the host 
cell and replicate their own genetic materials inside the cell. Since 1966 when Edward Tatum 
initially proposed to repurpose viruses for therapeutic gene delivery, gene therapy has come a 
long way from the construction of many types of viral vectors to their use in more than 3,000 
clinical trials to date [4, 47]. Viruses used for gene delivery systems include retrovirus, 
adenovirus, adeno-associated viruses, lentivirus, poxvirus, and herpes simplex virus as shown in 























genomes to render them replication-deficient for a safe gene delivery vector and to free up some 
space for the desired transgene to be incorporated. Table 1.1 shows the different characteristics, 
advantages, and disadvantages of the most commonly used viral gene delivery vectors. Viral 
vectors exhibit high transduction efficiency to different cell types while providing long term gene 
expression. However, they possess some drawbacks such as immunogenicity, oncogenicity, 
pathogenicity, natural tropism, and high cost of production and purification [49]. 
Table 5.1: The properties of different types of viral vectors. 
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Non-viral gene delivery vectors 
Safety, toxicity, and immunogenicity concerns along with the relatively small capacity 
for the therapeutic DNA of viral vectors have prompted the development of synthetic vectors not 
based on viral systems. Non-viral gene delivery vector uses “naked” DNA or plasmid DNA 
which when injected directly into certain tissues produces significant levels of gene expression, 
but lower than those achieved with viral vectors. Despite the safety and simplicity of large-scale 
production of non-viral vectors, low levels of transfection and transient gene expression are major 
limitations to their use. Treating diseases requires a continued and high-level of gene expression, 
which makes viral vectors better candidates for delivering the therapeutic genes. 
Importantly, the efficiency of naked DNA delivery can be improved dramatically when 
combined with other physical or chemical modifications. Physical vectors include gene gun, 
electroporation, particle bombardment, ultrasound utilization, and magnetofection, while 
chemical ones include cationic polymers and lipids [48]. Cationic polymers or lipids can form 
complexes by binding to the negatively charged DNA to form either polyplexes or lipoplexes, 
respectively [50]. As shown in Figure 1.6, naked DNA remains the most popular non-viral vector 
used in clinical trials, followed by lipofection, which involves cationic lipid/DNA complexes.  




Table 5.2: Summary of advantages and disadvantages of non-viral vectors. 
Non-viral vector Advantages Disadvantages 
Lipids 
DOTAP 
Condense DNA efficiently, 
commercially available 
Low efficiency, toxic 
DOTMA 







Promote endosomal escape, 
commercially available 





Toxic, limited efficiency 
PLL 
Biocompatible, biodegradable, 
Efficient in condensing DNA 







Poor endosomal escape, low 
efficiency 
Dendrimers 
(PMAM, PPI, ...) 
Higher generation show good 
transfection efficiency 
Non-biodegradable, higher 
generation are cytotoxic 
Peptides 
CPP 
Enhance cellular uptake and 
endosomal escape 
Low efficacy 
RGD Promote targeting Low efficacy 
NLS Promote nuclear import 
Low efficacy, complex 
dissociation before nuclear 
import 
1.6 ADENOVIRUS 
Adenovirus (Ad) was the first viral vector developed for gene therapy and was approved 
for clinical trials in 1990. Ad was isolated from human cultured adenoid tissue for the first time in 
1953, hence the term adenovirus [51]. Since then, 57 adenovirus serotypes have been isolated and 
classified into seven distinct subgroups (A to G) based on their immunological properties [52, 
53]. Ads have been associated with different pathophysiology, ranging from gastrointestinal to 
ocular to respiratory tract infections. Ad is a non-enveloped linear double-stranded DNA virus 
(26 ̶ 45 kbp), with an approximate diameter of 90-100 nm. The estimated mass of the Ad 
particle is at least 150 x 106 Da, of which 22.6 x 106 Da are DNA [54]. In 1959, the negatively 
stained EM pictures first revealed the icosahedral shape of the virus with long fibers extending 
from each of the 12 vertices [55, 56]. Ad is composed of eleven well-identified structural 
proteins, three of which are major proteins: hexons, pentons, and fibers (Figure 1.7A) [57]. 
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Hexon proteins are arranged in trimers and present in 240 copies that form the 20 faces and 30 
edges of the icosahedral capsid. Penton bases are present in 12 copies located at each apex. Each 
penton capsomere is made up of a fiber, a homotrimer protein attached to a pentameric protein, 
the penton base, that closes up the vertices of the capsid [58]. The adenovirus fiber protein is 
composed of three domains: the tail, shaft, and knob (Figure 1.7B) [59]. The first 17 residues 
from the amino (N)-terminus forms the tail and non-covalently attach the fiber to the capsid 
penton base. The shaft consists of 22 structural repeats downstream from the tail. The remaining 
carboxy (C)-terminal segment folds into the globular knob containing the receptor-binding 
domain [60].  
Figure 1.7: A schematic depiction of Ad structure enclosing double stranded DNA. (A) The 
icosahedral Ad capsid is composed of hexon proteins and penton bases from which fiber protein 
emanate. (B) The fiber protein incorporated into each of the 12 vertices of Ad capsid is a homo-






Ad infection is initiated by high-affinity binding (Kd = 1.7 nM) of the fiber knob to 
a cellular receptor known as Coxsackievirus-Adenovirus Receptor (CAR) [61, 62]. This 
interaction docks the virus to the cell allowing secondary binding of the penton base to αv 
integrins, which triggers the receptor-mediated endocytosis of the whole virus [62].  
1.7 ADENOVIRUS AS GENE DELIVERY VECTOR 
Adenoviruses have several features that make them among the most widely used vectors 
for gene therapy, where they account for 20.5 % of all ongoing gene therapy clinical trials [23]. 
First, Ad vectors can carry relatively large DNA payload (up to 35 kb), transduce a broad range 
of human cells including dividing and non-dividing cells. They are known for their high 
efficiency of transduction and their high levels of gene expression (though transient). Second, 
Ads have low pathogenicity in humans, they cause few and only mild symptoms associated with 
the common cold. Third, Ad vectors do not insert their genome into the host nucleus but store it 
as an episome. Therefore, there is a low probability of oncogenicity, disturbance of vital cellular 
genes or processes. Fourth, Ads are abundant in several serotypes, and most adults have been 
exposed to the commonly used Ad serotypes in gene therapy (serotypes 2 and 5). Fifth, Ad 
vectors are easy to propagate and purify at high titers, also they are relatively easy to manipulate 
using recombinant DNA techniques. The vectors, however, have certain drawbacks which limit 
their use as a safe and efficient gene delivery vector. These include the inflammatory response, 
pre-existing immunity in humans, liver and spleen sequestrations as well as the virus promiscuous 
tropism.  
After intravenous injection, Ad vectors induce an innate immune response that is 
maximal by 6 hours. This immune response results in inflammation of the transduced tissues and 
efficient clearance of the administered vectors. The inflammatory response is mediated by the 
virus fiber, capsid, and DNA, independent of viral gene transcription [63, 64]. Phagocytic 
antigen-presenting cells such as macrophages and dendritic cells take up the virus particles 
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through scavenger receptors [65]. Inside the cell, the virus is sensed through various intracellular 
molecular sensors such as Toll-like receptors (TLRs) [66]. Several cytokines are then released 
like tumor necrosis factor α (TNF-α), IL-6, IL-1ß, interferon γ (IFN-γ), and IL-12 and 
chemokines macrophage inflammatory protein (MIP)-2, IFN-γ-inducible protein 10 (IP-10), and 
RANTES [67, 68]. The infected cells are specifically destroyed via the formed cytotoxic T 
lymphocytes (CTL) [69]. After the fatal incident in the clinical trial of Jesse Gelsinger [42], it 
became evident that the innate immune system is highly activated by intravascular administration 
of high doses of Ad vectors [43]. This tragedy halted all gene therapy trials in the USA for six 
years [70, 71]. Subsequent animal experiments were able to reproduce the events, where an 
inflammatory response was lethal to mice at a dose of 1010 virus particles (vp) per mouse; and to 
large animal models at high doses, such as >1013 vp per kg [72]. High doses of adenoviral vectors 
were reported to cause hepatotoxicity [73] and acute inflammatory response in addition to a 
reduction in gene delivery efficiency [74]. The induction of innate immune responses is critical in 
adenoviral vector-based strategies. To allow efficient gene delivery, the Ad vector should have a 
minimal innate immune response. Ad vectors, however, could benefit from the virus’s intrinsic 
property of innate immune response to allow efficient activation of transgene-specific adaptive 
immune responses to be used in vaccine delivery.  
The adaptive immune response to adenoviruses is another obstacle in Ad vector 
development as a gene delivery vector. An estimated 80% of the human population have pre-
existing immunity to human adenovirus serotype 5 [37]. Even if they were not exposed before to 
Ad and do not possess neutralizing antibodies, they will develop resistance against reinfection if 
exposed to an Ad vector at a high concentration [75]. Ad surface antigens such as hexon, penton, 
and fiber induce the production of neutralizing antibodies [76]. These neutralizing Abs recognize 
the virus leading to rapid clearance from the circulation which would limit the number of 
administrations that can be done and reduce the efficiency of transgene expression. Many 
approaches, for example, development of alternative Ad serotypes, varying immunization routes, 
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and using prime-boost regimens are in the pre-clinical or clinical stages of development to avoid 
pre-existing immunities against adenoviruses [37]. From a general health perspective, it is 
advantageous to have long-term immunity against adenovirus infection, but from a gene delivery 
standpoint, the innate and adaptive immune responses to the virus limit the efficacy of an 
adenovirus vector. 
CAR is a 46-kDa single transmembrane protein that is widely spread in a range of tissues 
including the brain, liver, heart, lungs, kidneys, and specifically, localizes with αvß3 and αvß5 in 
cardiomyocytes (Figure 1.8) [61, 77]. CAR acts as a pathfinder protein, directing organ formation 
during embryogenesis and re-expressing this embryonic pattern after cytopathic damage [78]. In 
cultured cells, CAR induces the formation of cell aggregates and accumulates at cell-cell contacts 
[79]. Some cells such as primary and cancer cells do not express CAR on their surface, and thus 
are refractory to transduction by CAR-binding Ad vectors [80]. The dependence of Ad on CAR 
for binding to cells to be endocytosed creates the problem of promiscuous tropism. This 
highlights the need for Ad vectors with CAR-independent internalization for cancer gene therapy. 
Furthermore, nonspecific binding between motifs present on the virus and proteins on the cell 
membrane can induce promiscuous tropism. For example, RGD motif on the penton base of the 
virus binds to αv-integrin receptors [62], while KKTK motifs on the fiber protein bind to heparan 
sulfate proteoglycans, leading to a wide tropism [81, 82]. The biodistribution of Ad vector does 
not only depend on the receptor usage as anticipated by in vitro experiments. After systemic 
administration, Ad vectors are rapidly cleared from the bloodstreams and most of the viral dose is 
sequestered in the liver or phagocytosed by macrophages. This markedly reduces the therapeutic 
gene transduction and displays severe hepatotoxicity. This hepatic tropism is due to binding of 
blood coagulation factor X (FX) to the hypervariable region (HPV) of Ad hexon subunit, 
followed by the interaction of the Ad-FX complexes to heparan sulfate proteoglycan (HSPG) 
molecules which are present in high concentrations at the surface of Kupffer cells in the liver 
[83]. Furthermore, Ad fiber protein binds to erythrocytes expressing CAR. This traps the virus in 
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the blood circulation, thereby reducing liver infection [84]. Although decreasing hepatic tropism 
is desirable, binding the virus to RBCs leads to haemagglutination and affects the bio-distribution 
and specific targeting to the diseased cell. 
 
Figure 1.8: Promiscuous tropism of Adenovirus as CAR is widely spread in the body cells. A) 
Ad binds to CAR-positive cells via interaction between the knob of Ad fiber and CAR. B) Ad 
cannot bind to cells that lack CAR (CAR-negative cells) like cancer cells.  
There has been a rapid expansion in the use of adenoviral vectors for in vitro and in vivo 
gene delivery [85]. Ad vectors have been used to treat monogenic diseases since 1992 when the 
first in vivo application for genetic therapy was reported. The case involved the expression of 
alpha-1 antitrypsin cDNA within hepatocytes of a patient with alpha-1 antitrypsin deficiency 
[86]. This was followed by two unsuccessful treatments, one was an ornithine-transcarbamylase 
deficiency in 1999 [13], and the other was an X-linked severe combined immunodeficiency in 
2002 [87]. Over the next decade, safety concerns were raised against the application of viral 
vectors in humans and lead to a significant decline in studies [88]. Much of the research focus in 
that time then shifted toward developing less immunogenic viral vectors and AAV and lentiviral 
vectors emerged [89].  
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Despite these first impediments, Ads have returned to the light of human gene therapy in 
recent years being the most commonly studied viral vectors among clinical trials [23]. Ad vectors 
are now  used for 1) gene therapy [90, 91]; 2) anticancer therapies, for example oncolytic 
Adenovirus [92], 3) vaccine therapy, for example vaccines against tuberculosis [93], HIV [94], 
malaria [95], influenza [96], and Ebola [97]. Recently Ad vectors have been used to effectively 
deliver engineered CRISPR/Cas9 systems to targeted cells and/or tissues for efficient genome 
editing, which cannot be effectively accomplished by other viral systems [98].  
1.8 METHODS TO OVERCOME DRAWBACKS ASSOCIATED WITH ADENOVIRUS  
Genetic modification of Adenovirus  
The adenovirus problems can be addressed by modifying the virus either genetically or 
chemically. Ad genome is organized into early (E1, E2a, E2b, E3, and E4), intermediate (IVA2 
and IX), and late genes (L1, L2, L3, L4, and L5) according to the expression of genes during 
infection and multiplication. The genome of Ad has been engineered several times to develop 
safe and efficient vectors for gene therapy applications. The first-generation vectors had a partial 
deletion of E1 and E3 genes. E1 genes are necessary for activation of viral promoters, expression 
of both early and late genes, and encoding of oncogenic transforming functions of the virus. E3 
gene encodes proteins that subvert the host’s immune response and allows the persistence of 
infected cells. Therefore, deleting parts of E1 and E3 regions resulted in replication-deficient and 
non-oncogenic vectors. The deletion also allowed the insertion of approximately 5.1 kb of 
therapeutic genes without affecting viral titer and growth rate [99]. A human embryonic kidney-
derived line, HEK 293 cell line, has been transformed by the adenovirus E1 region to be able to 
propagate the first-generation vectors [100]. These vectors, however, still showed a strong 
immune response and would be contaminated with the replication-competent virus [101]. Second-
generation vectors were created by deleting E2A, E2B, and E4 from the genome of the first-
generation Ad vectors to overcome their problems. These new vector constructs have decreased 
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toxicity and result in prolonged gene expression in vivo but their production has become 
complicated. The new vector constructs also did not prevent leaky expression of viral proteins 
and rapid loss of therapeutic gene expression, and thus were not widely used in gene therapy 
[102]. The third-generation vectors, known as gutless or helper-dependent Ad vectors, lack all 
viral genes except the packaging and ITR sequences. They have the highest capacity among all 
vectors due to their ability to carry therapeutic genes up to 37 kb in size. Third generation Ad 
vectors also have long-term transgene expression, less contaminated with replicating virus 
particles, and are less immunogenic than first- and second-generation vectors [103].  
Genetic modifications of Ad have also addressed the tropism problem, evaded pre-
existing immunity, and changed the biodistribution of Ad vectors after systemic application. Ad 
attaches to its target cell via the knob domain of the fiber which is structurally conserved between 
different Ad serotypes. In 1995, the first replacement of the fiber knob of Ad-5 with that of Ad-3 
altered the viral tropism and enhanced the binding and entry especially into primary cells [104, 
105]. In addition to the exchange of the fiber knob domain, genetic modifications included 
exchanging knob and shaft domains [106], varying the length of the fiber [107, 108], the 
formation of knobless fibers [109], and replacing equivalent domains from human Ad with others 
from animal Ad in a strategy known as “ Xenotype switching” [110, 111]. These genetic 
modifications generated Ad chimeras with ablated natural tropism and specific cell transduction 
abilities. In addition to changing primary receptor binding, intracellular virus trafficking [112] 
and induction of immune responses [113] might be altered by fiber modification. 
Genetic modification of Ad has also reduced the immunogenicity problem of the virus. 
Since the capsid protein hexon is the main antigenic component [114, 115], attempts have 
included hexon exchange or replacement of immunodominant hypervariable regions (HVRs) of 
Ad-5 with that of other serotypes [116]. Genetic manipulations of the fiber knob also generated 
Ad-5 vectors carrying the Ad-3 knob [117]. These modifications lead to successful evasion of 
neutralizing antibodies that recognize the parental vectors. Furthermore, the liver sequestration of 
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Ad was markedly decreased by the insertion of mutations in the FX-binding domain of HVR and 
its replacement with HVR of other serotypes [118, 119]. However, genetic capsid modifications 
are difficult to perform as they potentially interfere with correct folding of capsid proteins and/or 
particle assembly.  
Chemical or Physical modification of Adenovirus 
Although genetic modifications overcome the most relevant barriers to the clinical 
application of Ad-based therapies, the development of a production system for such vectors has 
been hampered by technical complexity and low titers. In contrast, chemical/physical 
modification is performed after the production and purification of the vectors. Therefore, high 
vector titers can be obtained as well as conventional producer cells can be used. Besides, 
chemical modification of the Ad capsid can be performed in a way that modifies thousands of 
amino acids on the capsid surface simultaneously [120].While Physical modification can be 
obtained by coating the Ad surface without chemical linking bonds. The primary purpose of 
chemical/physical modification is to shield the Ad capsid proteins (hexon, penton, and fiber) from 
unwanted interactions with the host cells, ablate Ad tropism while maintaining the infectivity of 
Ad. Surface modification of a viral vector leads us to the term hybrid viral vector. In this review, 
a hybrid vector is a gene delivery vector that combines the beneficial features of a viral vector 
and a non-viral vector. We will discuss hybrid vectors in the context of the chemical 
modifications of adenovirus, in which a biocompatible, and non-toxic material (polymer, lipid, 
etc.) binds with adenoviral vector to enhance its gene delivery properties. 
Coating of Ad with polymers.  Two kinds of strategies have been commonly used for 
surface modification of the Ad with polymers: covalent coating and noncovalent coating through 
electrostatic interactions. This surface modification facilitates the evasion of the host immune 
response and the ablation of the Ad tropism. 
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Covalent coating of the Ad with hydrophilic polymers. The Ad capsid has approximately 
1800 exposed lysine residues located on the hexon, penton, and fiber proteins [121]. This allows 
covalent bonding between the polymers and the amine groups of the lysine residues on Ad 
surface [120]. Polyethylene glycol (PEG) and poly-N-(2-hydroxypropyl) methacrylamide 
(pHPMA) are representative polymers of chemical engineering to Ad vectors. 
Polyethylene glycol (PEG).  PEG is a hydrophilic neutrally charged biocompatible 
polymer [122] that is commonly used to reduce protein-protein interactions between therapeutic 
compounds and proteins in vivo [123]. Coating of Ad with PEG in a technique called 
“PEGylation” has been shown to prevent the undesirable interactions between the Ad and the host 
cell. PEGylation has helped Ad in evading the host immune response as well as ablating the Ad 
tropism. In 1999, O’Riordan et al. carried the first PEGylation of Ad which resulted in the escape 
of the PEGylated virus from the neutralizing antibodies (NABs) both in vitro and in vivo [39]. 
Later, Croyle et al. confirmed that PEG can shield the surface of Ad from NABs and evade the 
adaptive immune response [124, 125]. PEG can also attenuate the innate immune responses 
induced by Ad after systemic administration. Mok et al. first demonstrated that PEGylation of Ad 
reduced interaction with immune cells, such as macrophages [126]. Studies have shown that IL-6, 
IL-12, and TNF levels were significantly decreased after intravenous administration of PEGylated 
Ad vectors [127, 128]. Furthermore, PEGylation is a promising tool to address the Ad tropism 
problem. Ad depends on the specific receptor (CAR) for binding and internalization and has 
shown high liver tropism. Thus, for many cells types that lack Ad primary receptors, such as 
tumor cells, skeletal and smooth muscle cells, peripheral blood cells, ciliated airway epithelium 
cells, and hematopoietic stem cells [129], infection with Ad is difficult. PEGylation of Ad blocks 
CAR interactions and changes the vector particle diameter to avoid entrapment in liver 
fenestrations, allowing higher vector concentrations to reach the target cells. Although 
PEGylation is a practical approach to improve the efficacy and safety of Ad vectors for gene 
delivery, it has some drawbacks that should be noted. First, most of the experimental animals had 
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NABs against Ads, not against PEGylated Ads, thus the ability of PEGylated Ads to evade NABs 
needs to be further considered. Second, PEGylation can block the interaction with cells, blunting 
the cellular uptake, and transduction efficiency of Ad vectors. In this case, another approach 
should be adopted to enhance the cellular uptake of PEGylated Ad vectors. 
Poly-N-(2-hydroxypropyl) methacrylamide (pHPMA). pHPMA is a hydrophilic polymer 
that has multiple amino-reactive groups, allowing approximately 10–15 points of attachment to 
the virus [130]. Thus, pHPMA forms polymer “stitches” that covers the Ad with a dense and 
stable coating [131]. pHPMA, also have adequate reactive sites for subsequent covalent 
attachment to other polymers without biofunctionalization like PEG. Inspired by these advantages 
of pHPMA, Fisher et al. modified the Ad with a multivalent reactive 16.5 kDa pHPMA [132]. In 
this study, modified pHPMA-Ad vectors evaded NABs by approximately 80% and ablated the 
CAR tropism of Ad in A549 (Ad-permissive human lung carcinoma cell line) in vitro. pHPMA-
Ad vectors reduced liver transduction as well because the dense coverage of Ad blocked FX from 
binding to the Ad hexon . In summary, pHPMA-lation of Ad can blunt the interaction with the 
host proteins in a more effective way than PEGylation. However, this modification may result in 
undesired effects like the interference with regular capsid disassembly during gene delivery 
because of the multiple reactive sites of pHPMA that cross-link different Ad capsids together.  
Non-covalent coating of Ad. 
 
Cationic polymers. Different polymers have been utilized to noncovalently coat the Ad 
surface, including poly ethylenimine (PEI), poly-l-lysine (PLL), polyamidoamine dendrimer 
(PAMAM), poly amino ethers, and chitosan. Those polymers are cationic in nature and can form 
complexes with the negatively charged virus surface through electrostatic interactions. Because of 
its simplicity, safety, and the ability to maintain the virus infectivity [133], the non-covalent 
coating has been widely employed to modify Ad surface. Cationic polymers can change Ad 
tropism by blocking the receptor-mediated endocytosis and increasing the cellular uptake of the 
modified virus in CAR-deficient cells. PEI and PLL are the first cationic polymers to increase the 
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cellular uptake of Ad in cells refractory to infection such as ciliated airway epithelial cells, 
skeletal cells, and smooth muscle cells [73–76]. Although PLL and PEI are efficient transfection 
polymers, their toxicity is a significant limitation to their subsequent use. Thus, new polymers 
that demonstrate high infectivity and low toxicities have been developed including PLL-b-PEG 
[134], PEG-g-PEI [135], PEI-bile acid conjugated [136], EGDE-3,3′(aminoglycoside polymer) 
[137], and PNLG (methoxy polyethylene glycol-b-poly) [138]. Another advantage of cationic 
polymers is that they can block liver tropism in vivo, which allows the modified virus to reach the 
targeted cells in higher concentrations. Kim et al. showed that localization of Ad/PNLG complex 
in the liver was significantly reduced compared to the naked Ad [139]. Cationic polymers also 
reduce the host innate and adaptive immune response. This beneficial feature was observed when 
IL-6 levels decreased after the systemic administration of Ad/PNLG complexes [139]. Dodds et 
al. also reported that coating Ad with polycations led to partial protection of Ad against the 
neutralizing effect of Ad antiserum [140]. Other examples include PEI and APC, cationic 
polyethylene glycol derivatives, that tightly coat Ad, thus shielding the virus from NABs [141, 
142]. In conclusion, cationic polymers can shield Ad to redirect Ad tropism, reduce liver 
accumulation, and enhance cellular uptake in CAR-negative cells. Besides, coating Ad with 
cationic polymers reduces the innate and adaptive immune response to Ad. However, careful 
design of physically modified Ad/polymer complexes should be implemented, due to the possible 
associated limitations including nonspecific uptake in cells, cytotoxicity of polymers, and serum 
instability of the Ad/polymer complexes leading to their rapid dissociation in blood.  
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Cationic lipids. Cationic lipids have been used to modify Ad including lipofection [143], 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), DOTMA (N-[1-(2,3-
dioleyloxy)propyl]-N,N,N trimethylammonium chloride), DOTAP (1,2-bis(oleoyloxy)-3-
(trimethylammonio) propane), and DC-Cholesterol (3β[N-(N′, N′-dimethylaminoethane)-
carbamoyl] cholesterol). Cationic lipids are biodegradable, readily available commercially, and 
can be relatively easily modified for specific applications [1, 2, 8]. In aqueous media, cationic 
lipids are assembled into a bilayer vesicular-like structure called liposomes. Cationic liposomes 
can envelop Ad through electrostatic interaction with the negatively charged virus, and similarly 
can bind to the negatively charged cell surface to enhance their uptake [70]. Complexing 
adenovirus with cationic liposomes is effective in increasing adenoviral transgene expression 
particularly in CAR-deficient cells [144]. Liposome complexation also resulted in reduced 
immunogenicity of adenovirus [145, 146]. Our lab has previously produced Ad associated with 
PEGylated cationic liposomes composed of ternary lipids DOTAP, DOPE, and cholesterol that 
were able to infect cells in a receptor-independent manner and protect the virus from innate and 
humoral immune responses.  
Cell-Penetrating Peptides. Cell-Penetrating Peptides (CPP) are short peptides, typically 
less than 30 amino acids, that can deliver cargo across the cell membrane of mammalian cells 
[147]. They are typically classified as either polycationic, amphipathic, or hydrophobic. CPPs 
have been used to facilitate the transport of different therapeutic agents into cells, including 
plasmid DNA, siRNA, therapeutic proteins, viruses, and other various nanoparticles [148]. 
Penetratin [149], Tat [150], and polyarginine [151] are polycationic cell-penetrating peptides 
enriched with arginine and lysine that have been successfully used to modify adenovirus to 
enhance its translocation into different cell types [152]. CPPs can be associated with the virus 
covalently via genetic modification of the capsid proteins or chemical conjugation or 
noncovalently based on electrostatic interactions to the surface of the virus particle [153]. Our lab 
has previously produced CPP-PEG-Ad where PEGylated Ad was conjugated to different kinds of 
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CPP: Penetratin, TAT, Pep1, polyarginine. Penetratin-PEG-Ad showed the highest transduction 
efficiency in CAR-negative cells compared to other CPP modified Ad vectors and was able to 
extend the potential gene therapy treatments to a much broader range of cell types[151].  
1.9. HYPOTHESES AND OBJECTIVES OF PRESENT WORK 
The motivation of the present work was to develop a hybrid gene delivery vector that 
combines a fiberless Adenovirus (FlAd) and synthetic materials that maintain the efficiency of 
the virus while avoiding its drawbacks. 
The working hypothesis of this study is:  
(i) The function of fiber protein could be replaced by a PLL-g-PEG copolymer to 
augment the virus transduction efficiency and reduce its immune response. 
(ii) PLL-g-PEG copolymer would modify the cellular trafficking of the hybrid fiberless 
adenovirus vectors to affect the efficiency of expression of the target gene. 
Our rationale for investigating FlAd and PLL-g-PEG copolymers for gene delivery was that 
FlAd will have advantages over native Ad (NtAd) such as a reduced immune response and 
independence on CAR binding for cell transduction. Further, the coating of the FlAd with the 
copolymer can shield the virus hexon protein from an immune response as well as increase the 
transduction efficiency of the virus in cells that are refractory to infection with NtAd. 
The objectives of this study:  
(i) Investigate the effects of PLL-g-PEG copolymer on the physicochemical properties 
and the overall performance of the PLL-g-PEG-FlAd vector. 
(ii) Compare the cellular trafficking of PLL-g-PEG-FlAd vectors to the native 




Outline of this study: 
Chapter 2: 
Investigation of the effects of PLL-g-PEG copolymer on the physicochemical properties and the 
overall performance of the PLL-g-PEG-FlAd vector will be studied as follow: 
• Preparation of PLL-g-PEG-FlAd hybrid vector via electrostatic association between FlAd 
and PLL-g-PEG at various formulation factors (PLL Mwt, PEG Mwt, Degree of 
PEGylation, PLL-g-PEG amount (μg)/106 FlAd particles). 
• Studying the effect of these factors on the physicochemical properties as particle size, 
zeta potential as well as on the transduction efficiency in CAR-positive (HEK 293) and 
CAR-negative (NIH 3T3) cells. 
• Optimization of PLL-g-PEG-FlAd using response surface method (RSM) to achieve 
highest transduction efficiency in CAR-positive (HEK 293) and CAR-negative (NIH 
3T3) cells. 
Chapter 3: 
Investigation of optimized hybrid vectors on the overall performance of the PLL-g-PEG-FlAd 
vector will be studied in terms of: 
• Cytotoxicity on CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells. 
• Innate immune response via measurement of levels of proinflammatory cytokines 
produced from macrophages. 
• Serum stability when subjecting hybrid vectors up to 50% serum. 





Comparison of the cellular trafficking of PLL-g-PEG-FlAd vectors to the native adenovirus in 
both CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells will be achieved as follow:  
• Determination of the binding and internalization levels of hybrid vectors. 
• Investigation of the attachment of hybrid vectors to heparin sulfate proteoglycan 
receptors (HSPGs). 
• Determination of endocytic pathway for internalization of hybrid vectors.  
• Determination of effect of pH on endosomal escape of hybrid vectors. 
• Determination of cytosolic transport pathway of hybrid vectors. 
The broader impact of the project is its culmination in an improved gene delivery vector that 
would be a potential step in the top-down approach which fully replaces a viral vector with a 
synthetic one, possessing the same advantages but not the disadvantages of a virus. This project 
would also greatly impact society by transitioning gene therapy from a fringe medical treatment 
to common practice. Finally, no boundaries limit a discovery; every bump in the investigation 






DESIGN OF HYBRID PLL-G-PEG FIBERLESS ADENOVIRAL GENE DELIVERY 
VECTORS 
2.1 INTRODUCTION 
Several challenges need to be addressed when developing a gene delivery vector for an 
efficient and safe delivery of genes for any clinical application. Viral vectors account for nearly 
two-thirds of the gene therapy clinical trials [23]. Ads are among the most popular viruses used 
for gene therapy (20.5% of all trials) with Ad serotype 5 being the most commonly used serotype. 
Ad vectors can carry large DNA payloads, transduce both dividing and non-dividing cells with 
high levels of gene expression (though transient) [89, 154-156]. However, the vectors exhibit 
some drawbacks like immunogenicity and wide tropism which causes difficulty in cell-specific 
targeting [37, 72, 129]. The dependence of the virus on binding to the cell surface receptor 
Coxsackie Adenovirus receptor (CAR) for attachment and internalization leads to the wide 
tropism of the Ad vectors [157]. Most cancer cell [80, 158, 159], ciliated airway epithelium [160], 
smooth muscle cells [161], skeletal muscle cells, peripheral blood cells, dendritic cells, and 
hematopoietic stem cells [162] exhibit low levels of CAR and thus are refractory to Ad vector 
transduction. The immune response against the virus capsid and fiber proteins prevents the vector 
from transducing the target cells [163]. Further, pre-existing neutralizing antibodies against Ad 
would require frequent and high doses of the vector to be administrated to deliver the desired 
therapeutic response. Nonetheless, high doses of Ad vectors can cause hepatotoxicity and severe
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inflammatory response [73, 74]. 
One promising vector design strategy is to engineer adenoviruses with enhanced gene 
delivery properties. Ads have been genetically modified to reduce immunogenicity and undesired 
tropism of the virus, enhance gene transfer efficiency, and provide targeted delivery [109, 164-
169]. Replacing the knob of Ad serotype 5 with other serotypes ablated or altered the virus 
tropism [170]. For example, transduction levels of primary melanoma cells with Ad-5 with a 
knob of Ad-3 increased up to three folds when compared to Ad-5 control [171]. A novel tropism 
towards pancreatic cancer cells was also displayed upon replacing the fiber of Ad-5 with the fiber 
of Ad-16 or Ad-50 [172]. Furthermore, switching the Ad-5 hypervariable regions (HRVs) with 
those of Ad-48 plus exchanging the fiber knob with that of chimpanzee SAd-25 resulted in almost 
complete evasion of the neutralizing antibodies both in vitro and in vivo [114]. Studies have also 
shown that exchanging the hexon HRVs of Ad-5 by those of Ad-48 ablated hepatocyte 
transduction in vitro and reduced liver transduction in vivo [173] . 
An alternative solution involves the design of a hybrid viral vector consisting of a viral 
vector complexed with biomaterials that exhibits the benefits of the parental virus but are safer, 
more efficient, and less expensive. Cationic polymers [174, 175] or lipids [176, 177], are safe and 
robust biomaterials that were previously combined with DNA to form a non-viral vector capable 
of gene delivery. Cationic polymers include poly-L-lysine (PLL) [178, 179], polyethyleneimine 
(PEI) [180], chitosan [181, 182] and poly-N-(2-hydroxypropyl) methacrylamide (pHPMA) [183], 
as well as a variety of materials specifically designed for gene delivery. Non-viral vectors must 
efficiently deliver DNA into the nucleus of the targeted cell and circumvent the intracellular 
barriers including endocytosis, endosomal escape, and transport through the cytoplasm and across 
the nuclear membrane. Synthetic materials are generally less efficient than viruses in overcoming 
one or more of the intracellular barriers, which makes non-viral vectors less clinically relevant.  
In this chapter, we construct a hybrid vector in which the fiber part of adenovirus is 
removed, and its function is replaced with a synthetic material. Our lab has previously 
32 
constructed an adenovirus that lacks the fiber protein forming a fiberless adenovirus (FlAd) [184]. 
The fiber protein, specifically the knob, is essential for binding the virus to the Coxsackie 
adenovirus receptor (CAR) and is thus a major detriment of viral tropism [185]. After systemic 
administration of the virus, the fiber protein plays a role in the high transduction levels in the liver 
and the spleen as well as the innate immune response [186, 187]. Therefore, fiber truncation 
would reduce both the tropism and the immunogenic response problems. However, this fiber 
removal would result in a great reduction in the virus transduction efficiency (TE) due to the 
inability of the virus to attach to the CAR and induce internalization. We hypothesize that the 
cellular entry functions of FlAd can be replaced through physical modification of the virus with 
the cationic PLL-g-PEG copolymer.  
PLL is one of the first cationic polymers employed for gene delivery [179]. PLL is a 
linear polypeptide with the amino acid lysine as the repeat unit; thus, possesses a biodegradable 
nature. Upon complexing PLL with Ad, the formed PLL-Ad vector lead to an increase in the 
virus uptake and the transgene expression in cells compared to cells treated with Ad alone [188]. 
However, PLL-Ad vectors are rapidly bound to plasma proteins and are cleared from the 
circulation [189]. Besides, PLL elicits undesirable cytotoxicity at high concentrations which 
hampers its application [190]. One popular modification that can increase both the transfection 
ability and the circulation half-life of PLL-Ad vectors is coating the vector with polyethylene 
glycol (PEG) [191, 192]. PEG is a hydrophilic polymer that reduces the protein-protein 
interactions between therapeutics, proteins, and cells in vivo. PEGylation of Ad vectors decreases 
recognition by neutralizing antibodies and reduces the innate immune response to the virus [193, 
194]. Besides, PEGylation increases the vector circulation times and prolongs the transgene 
expression [124, 195]. However, PEGylation compromises the ability of the virus to interact with 
CAR, which reduces the transduction of Ad in cells [20]. This simultaneous ability to reduce 
immunogenicity and lower transduction efficiency in cells is known as the “PEG dilemma” [196]. 
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Therefore, using PLL-g-PEG copolymer would be a good approach to gain the benefits of PEG 
while retaining the infectivity of the virus.  
Based on this study, a PLL-g-PEG copolymer may be able to jointly eliminate the 
drawbacks addressed separately by each reagent. PLL-g-PEG-FlAd hybrid vector is expected to 
have improved transduction efficiency, and reduced immunogenicity. In this chapter, we report 
the formation of these hybrid vectors and investigate the variables that affect the physicochemical 
properties as well as the gene delivery efficiency such as PLL molecular weight, PEG molecular 
weight, Degree of PEGylation (DOP), and the ratio of PLL-g-PEG to the virus. 
2.2 MATERIALS AND METHODS 
Cell culture 
Mouse fibroblast cell line (NIH 3T3), and human embryonic kidney cell line (HEK 293) 
were purchased from the American Type Culture Collection (ATCC) (Manassas, VA). The HEK 
293 was cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS) (Mediatech, Inc., Manassas, VA). The 
NIH 3T3 cells were cultured in DMEM with 10% calf serum (CS) (Mediatech, Inc., Manassas, 
VA). Cells were maintained in a humidified atmosphere at 37ºC and 5% CO2. 
Adenovirus 
Recombinant adenovirus type 5 (Ad) encoding lacZ reporter gene and lacking the E1 and 
E3 native genes was generated from the native adenoviral plasmid, pAdEasy-1 (Addgene plasmid 
16400) and pShuttle-CMV-lacZ (Agilent, CA) [197, 198]. The virus was amplified in HEK 293 
cells and purified using ion-exchange chromatography in a Vivapure Adenopack purification kit 
following the manufacturer’s protocol (Sartorius Stedim, CO). Ad was concentrated and stored in 
phosphate-buffered saline (PBS), pH 7.4. The number of virus particles (vp) was determined by 
measuring UV absorbance at 260 nm (1 U ≈ 1012 virus particles/ml) [198].  
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Fiberless Adenovirus generation 
A Fiberless Ad serotype 5 plasmid (pAd5-FLAd) was generated using homologous 
recombination to remove the fiber gene from the native Ad plasmid (pAdEasy-1) [184]. Since the 
removal of the fiber severely reduced the infectivity of the virus, amplification of FlAd is 
required in 633 cell line that stably expresses fiber protein. Transfection of 633 cells with pAd5-
FlAd produced a virus with fiber protein but lacking the fiber gene. Passaging the virus on 633 
cells enriched the virus titer. The enriched virus was then used to produce FlAd through a final 
passage on HEK 293 cells. The virus was collected and purified using the Vivapure Adenopack 
purification kit following the manufacturer’s protocol (Sartorius Stedim Arvada, CO). The virus 
was quantified by measuring the absorbance of the viral DNA at a wavelength of 260 nm (1 U ≈ 
1012 virus particles/ml).   
FlAd is unable to infect cells since it lacks the fiber protein. While generally the virus is 
referred to as infectious particles, it is better to think about the particles as being potentially 
infectious. Not all NtAd or FlAd particles, however, are infectious or potentially infectious. 
Mittereder et al. showed that only about 5% of adenovirus particles are infectious [199]. The 
other 95% of the virus particles are thought to be inactive due to harsh conditions the viral 
particles go through during the purification steps. An assumption made in the present study was 
that only 5% of FlAd is potentially infectious.  
PLL-g-PEG copolymer synthesis 
PLL-g-PEG was synthesized via reacting the primary amines (-NH2) on the lysine chains 
of PLL-HBr (Sigma, Aldrich) with the succinimidyl ester group on the mPEG-NHS (Creative 
PEGworks, NC). Various masses of mPEG-NHS (0.5, 2, and 5 kDa) were added to 15 mg of 
PLL-HBr (1–5, 4–15, 15–30, and 30–70 kDa) dissolved in 200 μL of phosphate buffered saline 
(PBS) to create a library of PLL-g-PEG as shown in Table 2.1. For 5%, 10% and 25% grafting 
ratio, (3, 10, and 14 mg), (6, 21, and 51 mg), and (14, 51, and 128 mg) of PEG 0.5, 2 and 5 kDa 
were added to the dissolved PLL, respectively. The mixtures were allowed to react for 2 hours 
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before being washed with ultrapure water in a 10 kDa centrifugal concentrator. After 3 washes, 
each grafted copolymer was lyophilized and stored at -20°C. 
The grafting ratio of each PLL-g-PEG was determined using proton nuclear magnetic 
resonance spectroscopy (1H NMR). Lyophilized polymer was dissolved in D2O, and 1H NMR 
spectroscopy was performed using a Bruker Avance INOVA 400 MHz spectrometer. The 
grafting ratio, or PEG chains per PLL chain, was determined by integrating the PLL and PEG 
peaks at 4.3 ppm and 3.7 ppm, respectively (Appendix I).  
Formation of PLL-g-PEG-FlAd vector  
 
PLL-g-PEG-FlAd vectors were prepared through electrostatic attraction between the 
positively charged copolymer and the negatively charged FlAd. PLL-g-PEG was dissolved in 
PBS, pH 7.4, followed by filtration through a 0.2 μm syringe filter. The required volume of the 
virus (according to the MOI used) was added dropwise to the copolymer to achieve a final 
concentration of 0.001 to 1 µg PLL-g-PEG/106 vp. Subsequently, the solution was mixed by 
gentle aspiration with the pipet tip and allowed to incubate for 10–30 min at room temperature 
before further use.  
Transduction efficiency studies 
 
The transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd vectors was studied on 
HEK 293 and NIH 3T3 cells. Cells were seeded for 24 hours before infection at 5 × 104 cells per 
well in 24 well plates. The cell culture medium was replaced with serum-free DMEM at 50% of 
the typical well culture volume (for example, 0.25 ml in a 24-well plate). The cells were then 
infected with the virus or hybrid viral vector using a MOI of 100 for HEK 293 cells and 250 for 
NIH 3T3 cells. Four hours later, the medium was replaced with fresh cell culture medium 
(containing serum), and cells were incubated for 48 hours. LacZ expression was quantified using 
the chemiluminescence based Beta-Glo assay (Promega Inc., Madison, WI). The reporter gene 
expression was measured in terms of relative light units (RLU) with a Lumat LB9507 
36 
luminometer (EG&G, Berthold, Bundoora, Australia). The gene expression was then normalized 
to total cellular protein determined using the bicinchoninic acid assay (BCA assay) (Pierce, 
Rockford, IL) to account for different cell densities at the time of reporter gene measurement.  
Negative stain Transmission Electron Microscopy 
For NtAd, FlAd and PLL-g-PEG-FlAd samples, each sample was placed on a copper grid 
and incubated for 2 minutes. Excess sample was wicked off the grid using a filter paper. A drop 
of 2% uranyl acetate stain was added and let sit for one minute. Excess stain was again wicked 
off using filter paper and the grid was dried for 15 minutes before viewing with JEOL JEM 2100 
Transmission Electron Microscope. 
Size and zeta potential measurements 
NtAd, FlAd and PLL-g-PEG-FlAd samples were prepared as described above and diluted 
to a concentration of 106 vp/ml and the effective hydrodynamic diameter was measured using a 
ZetaPALS particle size analyzer (Brookhaven Instrument, Inc., Holtsville, NY). The 
measurements were performed in triplicate with 10 repeated measurements at 10-second intervals 
for each sample. Zeta potential was also measured for vectors diluted to a concentration of 109 
vp/ml and measured in triplicate with 10 repeated measurements per sample.  
Statistical analysis Design of Experiment (DOE) 
D-optimal experimental design, one of the response surface model (RSM) design tools, 
was used to evaluate the effect of the independent variables on the transduction efficiency (TE) of 
PLL-g-PEG-FlAd vectors in CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells. The 
independent variables (factors) were the ratio of PLL-g-PEG to FlAd, degree of PEGylation, 
molecular weight (Mwt) of PLL and PEG, which were indicated by (a), (b), (c), and (d) 
respectively. Two dependent variables (responses) were the transduction efficiency (TE) of PLL-
g-PEG-FlAd vectors in CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells. Table 2.2 
summarizes all the factors and responses with their ranges. The range of the factors was chosen in 
accordance with the results of screening preparatory experiments. 
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A total number of 37 experimental runs with three replications of the central point were 
suggested by the software, as shown in Table 2.3. The experimental runs and data analysis were 
performed using Design Expert® v. 12 (Design Expert® Software, MN) to generate three-
dimension (3D) surface plots for each response. 
Check points analysis and model validation  
Check point analysis was carried out to establish the model prediction performance. 
Three check points were chosen around the optimal area of the design space. Actual values were 
obtained from lab experiments that were performed in triplicates. Predicted values were obtained 
from the point prediction of the Design Expert® v.12 software. Predicted and actual values were 
compared to determine the percentage bias between the experimental values and the behavior 
described by the model. The percentage bias was calculated from the following equation [200]:  
Bias % = 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒−𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑣𝑎𝑙𝑢𝑒
× 100 
2.3 RESULTS  
PLL-g-PEG-FlAd vector formation 
 
PEG grafted PLL copolymer was synthesized by conjugating NHS-activated mPEG to ε-
amine groups on the PLL, as shown in Figure 2.1. In this study, a library of PLL-g- PEG 
copolymers was synthesized with different molecular weights of PLL (1–5, 4–15, 15–30, and 30–
70 kDa), PEG (0.5, 2, and 5 kDa) and different degrees of PEGylation (DOP) (5, 10, and 25%) as 
listed in Table 2.1. The degree of PEGylation on the PLL backbone was calculated from 1H 
NMR spectra analysis (data not shown), based on the relative integration ratio of a single –CH2− 




Figure 2.1: Structure of PLL-g-PEG grafted copolymer synthesized by interaction of PLL-HBr 




Table 2.1: Composition of synthesized PLL-g-PEG copolymers. 
PLL Mwt (kDa) 
Degree of PEGylation 
(DOP) 
PEG Mwt (kDa) 
0.5  2  5  
1–5 
5% PLL1-5-g5%-PEG0.5 PLL1-5- g5%-PEG2 PLL1-5-g5%-PEG5 
10% PLL1-5-g10%-PEG0.5 PLL1-5- g10%-PEG2 PLL1-5-g10%-PEG5 
25% PLL1-5-g25%-PEG0.5 PLL1-5- g25%-PEG2 PLL1-5-g25%-PEG5 
4–15 
5% PLL4-5-g5%-PEG0.5 PLL4-5- g5%-PEG2 PLL4-5-g5%-PEG5 
10% PLL4-5-g10%-PEG0.5 PLL4-5- g10%-PEG2 PLL4-5-g10%-PEG5 
25% PLL4-5-g25%-PEG0.5 PLL4-5- g25%-PEG2 PLL4-5-g25%-PEG5 
15–30 
5% PLL15-30-g5%-PEG0.5 PLL15-30- g5%-PEG2 PLL15-30-g5%-PEG5 
10% PLL15-30-g10%-PEG0.5 PLL15-30- g10%-PEG2 PLL15-30-g10%-PEG5 
25% PLL15-30-g25%-PEG0.5 PLL15-30- g25%-PEG2 PLL15-30-g25%-PEG5 
30–70 
5% PLL30-70-g5%-PEG0.5 PLL30-70- g5%-PEG2 PLL30-70-g5%-PEG5 
10% PLL30-70-g10%-PEG0.5 PLL30-70- g10%-PEG2 PLL30-70-g10%-PEG5 
25% PLL30-70-g25%-PEG0.5 PLL30-70- g25%-PEG2 PLL30-70-g25%-PEG5 
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PLL-g-PEG-FlAd vectors were formed via the electrostatic interaction between the 
positively charged cationic PLL-g-PEG copolymer and the negatively charged Ad surface as 
shown in Figure 2.2.  
Figure 2.3: Schematic representation of FlAd coated with PLL-g-PEG, step 1: Formation of 
Fibereless Ad by genetic truncation of fiber proteins, step 2: Electrostatic attraction between 
negatively charged FlAd surface and positively charged PLL-g-PEG copolymer. 
Transmission Electron Microscopy (TEM) 
TEM was used to characterize the morphologies of PLL-g-PEG-FlAd vectors compared 
to FlAd (Figure 2.3). Photomicrographs of FlAd showed the hexon structure and the icosahedral 




Figure 2.3: (A) Negative Stain TEM of FlAd alone, scale bar =100 nm. (B) Negative Stain 
Transmission Electron Microscopy of PLL4-5-g5%-PEG5 hybrid vector.  
Transduction efficiency of PLL-g-PEG-FlAd 
 
Transduction is a process by which DNA is introduced into a cell by a virus or a viral 
vector. FlAd had a packaging sequence encoding a reporter lac-Z gene. The efficiency of the 
virus in infecting the cells is measured by the level of the reporter gene expression which is called 
transduction efficiency (TE). Transduction efficiency of the PLL-g-PEG-FlAd vectors was 
compared to that of NtAd and FlAd in CAR-positive (HEK 293) and CAR-negative (NIH 3T3) 
cells. Several factors affected the transduction efficiency of hybrid vectors including multiplicity 
of infection (MOI), PLL Mwt, PEG Mwt, degree of PEGylation, and ratio of PLL-g-PEG to 
FlAd. Each factor was tested one at a time to determine the suitable levels that would lead to the 
best gene delivery. 
Multiplicity of infection (MOI) effect on transduction efficiency by PLL-g-PEG-FlAd 
The amount of virus particles added per cells for infection, the multiplicity of infection 
(MOI), is a critical factor in controlling TE. In order to optimize the transduction of PLL-g-PEG-
FlAd vectors, we studied the effect of varying the MOI of hybrid vectors on HEK 293 and NIH 




increment in gene expression of the particles over FlAd was studied (Figure 2.4). In HEK 293 
cells, the transduction efficiency of the hybrid vector increased with the increase in MOI, then 
transduction efficiency declined at 500 and 1000 (X-gal stained cells also confirmed the results, 
data not shown). In NIH 3T3, FlAd were not able to transduce the cells at sufficient levels at all 
MOIs, while hybrid vectors transduced the cells at MOI ≥ 250. PLL-g-PEG-FlAd vectors showed 
the maximum transduction efficiency in HEK 293 and NIH 3T3 cells at MOI of 100 and 250, 
respectively. These MOI values were selected to be used in further studies. 
 
Figure 2.3: Effect of MOI on transduction efficiency of PLL4-5-g25%-PEG5 particles in HEK 293 
and NIH 3T3 cells. The PLL-g-PEG-FlAd particles were formed at a ratio of 0.001 PLL-g-PEG 
μg/106 vp. The data points represent the mean ± standard deviation (n=3).  
PLL molecular weight effect on transduction efficiency by PLL-g-PEG-FlAd 
A wide range of PLL molecular weights (Mwts) from 1 to 70 kDa was tested to prepare 
PLL-g-PEG-FlAd vectors as shown in Figure 2.5. The transduction efficiency of the formed 
hybrid vectors decreased at PLL Mwt > 15-30 kDa. PLL of high Mwt (70 ̶ 150 kDa) was 
excluded from further studies as the formed hybrid vectors did not transduce neither HEK 293 








































Figure 2.3: Effect of PLL molecular weight on transduction efficiency of PLL-g-PEG-FlAd 
particles in (A) HEK 293 and (B) NIH 3T3 cells. The PLL-g-PEG-FlAd particles were formed 
with PLL molecular weights of 1–5, 4–15, 15–30, 30–70, and 70–150 kDa. The molecular weight 
of PEG was held constant at 5 kDa PEG and 25% DOP and amount of PLL-g-PEG/ FlAd equal to 
1 μg/106 vp. The data points represent the mean ± standard deviation (n=3).  
PEG molecular weight effect on transduction efficiency by PLL-g-PEG-FlAd 
 Different molecular weights of PEG (0.5, 2 ,5, and 10) were used to prepare PLL-g-
PEG-FlAd and the effect of variation of PEG Mwt on the transduction efficiency of hybrid 
vectors was also studied. High Mwt PEG (10 kDa) resulted in very poor transduction efficiency 
compared to other Mwts of PEG (Figure 2.6). This led us to exclude 10 kDa PEG from further 
studies. 
  
Figure 2.6: Effect of PEG molecular weight on transduction efficiency of PLL-g-PEG-FlAd 
particles in (A) HEK 293 and (B) NIH 3T3 cells. The PLL-g-PEG-FlAd particles were formed 
with PEG molecular weights of 0.5, 2, 5, and 10 kDa. The molecular weight of PLL was held 
constant at 4–15 kDa and DOP 25% and amount of PLL-g-PEG/ FlAd =1μg/106 vp. The data 





















































































































































Degree of PEGylation (DOP) effect on transduction efficiency by PLL-g-PEG-FlAd 
The effect of different degrees of PEGylation (5, 10, 25, 30, and 40%) on the 
transduction efficiency of the prepared hybrid vectors is shown in Figure 2.7. The optimum range 
of DOP was 5–25%, while increasing the DOP to 30% and 40% led to a reduction in the 
transduction efficiency of hybrid vectors. Further experiments were conducted using PLL-g-PEG 
at DOP: 5, 10, and 25%. 
  
Figure 2.3: Effect of degree of PEGylation on transduction efficiency of PLL-g-PEG-FlAd 
particles in (A) CAR+ HEK-293 and (B) CAR– NIH 3T3 cells. The PLL-g-PEG-FlAd particles 
were formed with degree of PEGylations of 5, 10, 25, 30, and 40%. The molecular weight of PLL 
was held constant at 4–15 kDa and 5 kDa PEG and amount of PLL-g-PEG/ FlAd =1 μg/106 vp.  
PLL-g-PEG/FlAd ratio effect on transduction efficiency by PLL-g-PEG-FlAd 
A range of ratios of PLL-g-PEG to FlAd from 0.00001 to 10 µg PLL-g-PEG /106 vp was 
used to study their effect on the transduction efficiency. The hybrid vector ability in delivering 
genes started to increase at 0.001 PLL-g-PEG µg/106 vp. Afterwards, transduction efficiency 
decreased at concentrations higher than 1 µg /106 vp (Figure 2.8). The range of 0.001 to 1 PLL-g-

































































Figure 2.3: Effect of ratio of PLL-g-PEG/106 vp on transduction efficiency of PLL-g-PEG-FlAd 
particles in (A) CAR+ HEK 293 and (B) CAR– NIH 3T3 cells. The PLL-g-PEG-FlAd particles 
were formed with PLL 4–15 kDa, PEG 5 kDa and degree of PEGylation of 25%. The data points 
represent the mean ± standard deviation (n=3).  
Particle size and zeta potential of PLL-g-PEG-FlAd  
 
The particle size of NtAd, FlAd, and PLL-g-PEG-FlAd vectors were measured. The 
mean particle size of NtAd and FlAd, was 108 ±2.2 nm and 115 ±3.4 nm, respectively. Upon 
complexing FlAd with PLL-g-PEG, the particle size of the formed hybrid vector increased. The 
particle size of hybrid vectors varied according to the formulation parameters including PLL 
Mwt, DOP, and amount of PLL-g-PEG/ FlAd (Figure 2.9).  
The particle size of hybrid vectors is directly proportional to the Mwt of the PLL used in 
the preparation of the vector. As PLL Mwt increased from 1–5 to 30–70 kDa, the particle size of 
the formed hybrid vectors increased from 259 to 570 nm at a concentration of 0.001 μg/106 vp, 
respectively. However, the particle size of hybrid vectors prepared with PLL (70 –150 kDa) 
exceeded 1 µm and this Mwt was excluded from further studies. Using higher concentrations of 
PLL-g-PEG/FLAd also led to the formation of larger sized particles. For example, hybrid vectors 
prepared with PLL-g-PEG at 0.001μg/106 vp had a particle size range of 270 to 984 nm which 






























































Figure 2.3: Mean particle size of PLL-g-PEG-FlAd formed with different PLL molecular 
weights of 1–5, 4–15, 15–30, 30–70, and 70–150 kDa, and 5kDa PEG at 25% DOP, at two 
concentrations: a) Low concentration = 0.001µg PLL-g-PEG /106
 
vp, b) High concentration = 
1µg PLL-g-PEG /106
 
vp. Errors are standard deviations (n=3; 10 readings for every sample). The 
size of FlAd without addition of copolymers was 115 ± 3.4 nm. 
The particle size of the formed hybrid vectors also changed as a function of degree of 
PEGylation of the copolymer used. As shown in Figure 2.10, the particle size of the vectors 
increased as the DOP increased. The particle size of the vectors was in the range of 139–259 nm 
when prepared with PLL-g-PEG at 5–25%. However, the particle size increased to a range of 260 
– 335 nm at 30–40% DOP according to the PLL used. Therefore, further studies were conducted 
using 5 – 25% DOP. 
 
Figure 2.3: Effect of degree of PEGylation on mean particle size of PLL-g-PEG-FlAd particles. 
The particles were formed with PEG 5 kDa and amount of PLL-g-PEG/ FlAd equal to 0.001 
























































The zeta potential of NtAd, FlAd, and PLL-g-PEG-FlAd was also measured. NtAd and 
FlAd had a negative charge of -21.3 ± 0.5 and -17.7 ±1.5 mV, respectively. Upon complexing 
FlAd with PLL-g-PEG, the zeta potential showed a significantly higher positive charge with a 
range of +1.74 to +17.3 mV (Figure 2.11). The zeta potential was studied as a function of PLL 
Mwt, DOP, and concentration of PLL-g-PEG/FlAd as well. Both the increase in the Mwt of PLL 
and the concentration of PLL-g-PEG/FlAd resulted in an increase in the positive surface charge 
of hybrid vectors formed. For example, PLL-g-PEG-FlAd prepared with PLL (15–30 kDa) at 1 
μg/106 vp showed the highest zeta potential with values of +17.3 and +9.5 mV at 5% and 25% 
DOP, respectively. The zeta potential of the formed hybrid vectors decreased upon increasing the 
DOP which can be correlated to the increase in the particle size of the hybrid vector as well.  
 
Figure 2.3: Zeta-potential of PLL-g-PEG-FlAd prepared with different PLL Mwt, PEG 5 kDa at 



























Optimization of transduction efficiency of PLL-g-PEG-FlAd in CAR-Positive And CAR-
Negative Cells Using Design Of Experiment (DOE): 
The transduction efficiency of PLL-g-PEG-FlAd in CAR-positive and CAR-negative 
cells varied as a factor of PLL and PEG Mwt, degree of PEGylation (DOP) and ratio of PLL-g-
PEG/FlAd. Hence, an optimization statistical model was required to achieve the maximum 
response (TE) in each cell type. Table 2.2 summarizes all the factors and responses with their 
ranges which were chosen in accordance with the results of preparatory experiments. A total 
number of 37 experimental runs were suggested by the software and are shown in Table 2.3. In 
CAR-positive (HEK 293) cells, the transduction efficiency of PLL-g-PEG-FlAd vectors varied 
from 0.1 to 3.5 folds compared to FlAd according to formulation parameters. In contrast, the 
transduction efficiency of PLL-g-PEG-FlAd vectors varied from 0.1 to 10.2 folds compared to 
FlAd in CAR-negative (NIH 3T3) cells according to formulation parameters. 
Table 2.3: Factors and responses with their ranges. 












% Numeric 5% 25%  
C PLL Mwt kDa Categoric 1–5 30–70 4 








TE* in  
NIH 3T3 
0.35 10.2 
*TE: Transduction efficiency 
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Table 2.3: 37 experimental runs with three replications of the central point (n=3). 
 




B: PEG% C: PLL D: PEG 
Transduction 
efficiency in HEK 
293 cells 
Transduction 
efficiency in NIH 
3T3 cells 
1 0.001 5 15-30 5 0.14 4.2 
2 0.001 25 4-15 5 1.3 2.9 
3 1 25 4-15 0.5 2.2 1.2 
4 0.001 25 1-5 5 0.8 1.1 
5 1 5 15-30 2 0.12 0.8 
6 1 5 4-15 5 1.2 10.2 
7 0.1 10 4-15 2 1.2 2 
8 1 25 15-30 0.5 3.5 3.6 
9 0.001 5 1-5 2 0.4 0.35 
10 1 10 15-30 5 0.61 2.5 
11 1 25 15-30 0.5 3.5 3.4 
12 0.1 5 30-70 5 0.8 0.95 
13 0.001 10 15-30 2 1.6 1.4 
14 0.001 25 1-5 0.5 0.5 0.7 
15 1 5 4-15 2 0.4 3.3 
16 1 5 30-70 0.5 0.1 0.89 
17 0.1 25 30-70 2 0.12 0.92 
18 0.1 10 1-5 5 1.5 1.8 
19 0.001 5 30-70 2 1.2 1.2 
20 1 5 30-70 5 0.1 0.65 
21 0.001 5 15-30 5 0.14 4.2 
22 0.001 5 4-15 0.5 0.2 1.6 
23 1 10 30-70 2 0.2 1.6 
24 0.1 25 15-30 5 0.7 1.2 
25 1 10 1-5 0.5 1.4 4.3 
26 1 25 30-70 5 0.3 0.61 
27 0.001 5 4-15 0.5 0.2 2.3 
28 1 5 1-5 5 3.2 3.9 
29 1 25 1-5 2 1.9 8 
30 1 25 4-15 0.5 2.2 1.2 
31 0.001 25 30-70 5 0.1 0.4 
32 0.01 10 30-70 0.5 2 1.6 
33 1 5 1-5 2 1.1 2.5 
34 0.001 25 15-30 2 2.1 2.1 
35 1 25 4-15 2 1.2 2.5 
36 0.1 5 15-30 0.5 0.5 5.6 
37 0.1 5 15-30 0.5 0.1 5.5 
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The transduction efficiencies in CAR-positive (HEK 293) and CAR-negative (NIH 3T3) 
cell results were fitted to the quadratic model generated by the D-optimal design. The adequacy 
of each model was verified using ANOVA test. The P-values for the model was <0.0001. Table 
2.4 shows a summary of the multiple regression analysis of the two generated quadratic models.  
Table 2.3: Summary of the results of the regression analysis for the D-optimal design after fitting 
to the quadratic model. 
Parameter Response 1: 
TE* in HEK-293 cells 
Response 2: 
TE* in NIH-3T3 cells 
Significance < 0.0001 < 0.0001 
R-squared 0.9943 0.9950 
Adjusted R-squared 0.9795 0.9807 
Predicted R-squared 0.8929 0.7996 
Adequate precision 28.5 35.7 
*TE: Transduction efficiency 
In CAR-positive model and according to the P-value of the coefficient estimate, the DOP 
and Mwt of PLL are highly significant in the model (P-value<0.0001), whereas the Mwt of PEG 
is less significant (P-value <0.001). The ratio of PLL-g-PEG/FlAd shows no significance effect in 
this model.  
The transduction efficiency can be expressed as a function of ratio of PLL-g-PEG/FlAd 
(A), Degree of PEGylation (B), PLL Mwt (C), and PEG Mwt (D), levels of each factor are 
annotated as [1], [2] or [3] as shown in Equation (1): 
Transduction efficiency in HEK 293 cells = +0.8080 +0.1000 A +0.4655 B +0.1619 C[1] 
+0.0391C[2] +0.1477 C[3] +0.1448 D[1] -0.2349 D[2] +0.2710 AB +0.7956 AC[1] -0.1474 
AC[2] -0.1879 AC[3] -0.0399 AD[1] -0.1442 AD[2] -0.1879 BC[1] +0.0099 BC[2] +0.5202 
BC[3] +0.5904 BD[1] -0.2538 BD[2] -0.6418 C[1]D[1] -0.3621 C[2]D[1] +0.4003 C[3]D[1] -
0.2337 C[1]D[2] +0.0775 C[2]D[2] +0.3241 C[3]D[2] +0.7367 A² -0.4375 B²…….……….Eq (1) 
In CAR-negative model and according to the P-value of the coefficient estimate, the 
PLL-g-PEG/FlAd ratio, the Mwt of PLL, and the Mwt of PEG are highly significant in the model 
(P-value <0.0001), whereas the DOP is less significant (P-value <0.001).  
  
51 
The transduction efficiency can be expressed as a function of ratio of PLL-g-PEG to 
FlAd (A), Degree of PEGylation (B), PLL Mwt (C), and PEG Mwt (D), levels of each factor are 
annotated as [1], [2] or [3] which has been shown in Equation (2): 
Sqrt(Transduction efficiency in NIH 3T3 cells)= +1.48 +0.2275 A-0.0943 B+0.1189 C[1] 
+0.2630 C[2] +0.0536 C[3] -0.0382 D[1] -0.1844 D[2] +0.1535 AB+0.4180 AC[1] +0.0614 
AC[2] -0.2796 AC [3]+ 0.0058AD[1] +0.0570AD[2] +0.3561BC[1] -0.3160BC[2] -0.1095BC[3] 
-0.0393BD[1] +0.1448BD[2] -0.0782C[1]D[1] -0.5570C[2]D[1] +0.5755C[3]D[1] 
+0.1610C[1]D[2] -0.1374C[2]D[2] -0.3482C[3]D[2] +0.1855A²-0.2407B²   ……………..  Eq (2) 
 
Figure 2.12 and Figure 2.13 demonstrate the 3D plots of D-optimal model in CAR-
positive (HEK 293) cells and CAR-negative (NIH 3T3) cells. In HEK 293 model, the interaction 
between the ratio of PLL-g-PEG/FlAd and PLL Mwt (AC), and between PLL Mwt and PEG Mwt 
(CD) were significant with 15% and 19% contribution of the overall factors (P<0.0001). In NIH 
3T3 model, the interaction between the ratio of PLL-g-PEG/FlAd and PLL Mwt (AC), and 
between PLL Mwt and PEG Mwt (CD) were significant with 30% and 12% contribution of the 
overall factors (P<0.0001). From the model plots, it can be inferred that there is an inverse 
relationship between the Mwt of PLL and the transduction efficiency in both cells at some 
concentrations and PEG Mwts. For example, hybrid vectors prepared with 30-70 kDa showed 
less than one-fold increase in transduction efficiency compared to those prepared with 1-5 kDa 
and 4-15 kDa vectors that showed 3.5- and 2-fold increase in transduction efficiency at 5 kDa 
PEG, 5% and 1 µg PLL-g-PEG/ 106 FlAd in HEK 293 cells.  In NIH 3T3 cells, hybrid vectors 
prepared with 30-70 kDa showed less than one-fold increase in transduction efficiency compared 
to those prepared with 1-5 kDa and 4-15 kDa vectors that showed 4- and 10.2-fold increase in 
transduction efficiency at 5 kDa PEG, 5% and 1 µg PLL-g-PEG/ 106 FlAd.
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Figure 2.3: Continued.  
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Figure 2.33: Continued.  
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Model validation and optimization 
Model optimization 
 To obtain the optimized factors and levels required for maximum transduction efficiency 
in either cell line, the optimum point (goal) was set to maximum response. Figures 2.14 (A) and 
(B) show the desirability values for the various conditions in HEK 293 and NIH 3T3 cells, 
respectively. Based on HEK 293 model prediction, the optimum point will occur in PLL Mwt: 
15–30 kDa, PEG Mwt: 0.5 kDa, degree of PEGylation: 25%, and PLL-g-PEG/ FlAd: 1 µg/10 6 
vp, which will be designated PLL15-30-g0.5-PEG25% (S1) for further use in our study. Based on NIH 
3T3 model prediction, the optimum point will occur in PLL Mwt: 4–15 kDa, PEG Mwt: 5 kDa, 
degree of PEGylation: 5%, and PLL-g-PEG/ FlAd: 1 µg/10 6 vp, which will be designated PLL4-
15-g5-PEG5% (S2) for further use in our study. 
 
 
Figure 0.14: Contour plots of optimized PLL-g-PEG-FlAd vectors showing the highest 
desirability of transduction in A) HEK 293 and B) NIH 3T3 cells.  
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To sum up, transduction efficiency of NtAd, FlAd, and selected hybrid vectors are 
demonstrated in Figure 2.15. FlAd lost almost 75% of its ability to transduce CAR-positive (HEK 
293) cells compared to NtAd. However, the selected hybrid vector S1 restored 85% of the lost 
infectivity, where the transduction efficiency increased 3.5 folds compared to FlAd. In CAR-
negative (NIH 3T3) cells, the transduction efficiency of NtAd and FlAd was almost negligible. 
However, the selected hybrid vector S2 was able to transduce the cells with an efficiency 10.2 
folds compared to FlAd. 
 
Figure 2.15: Transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd in HEK 293 and NIH 
3T3 cells. PLL15-30-g25%-PEG0.5-FlAd (S1), and PLL4-15-g5%-PEG5-FlAd (S2) were used to 
transduce HEK 293 and NIH 3T3 cells at 1 µg PLL-g-PEG/106vp, respectively. X-axis is 
Relative Light Units (RLU) per µg total protein in cellular lysate. # p<0.0001 (values were 
compared to FlAd).  
Model validation 
 In order to characterize an analytical method as robust, it must be able to predict 
responses with small differences from the experimental data. Thus, the validity of models was 
evaluated by experimentally preparing and characterizing the PLL-g-PEG-FlAd vectors in 
optimized points suggested by the model. Table 2.5 shows the results obtained of the three chosen 































for the D-optimal quadratic models. There is a good agreement between the actual and predicted 
responses as seen in the low values of % bias in between.  
Table 0.5: Check Point analysis results for responses.  
 HEK 293 cells NIH 3T3 cells 
Hybrid 
vector 
Actual TE Predicted TE %Bias Actual TE Predicted TE %Bias 
P1a 7.7 7.9 2.5 1.84 1.9 3.2 
P2b 1.34 1.3 3.1 1.3 1.1 18.2 
P3c 1.84 1.6 15 8.3 7.3 13.7 
a P1= PLL (1–5), PEG (2), 25%, 1µg/106 vp. 
b P2 = PLL (15–30), PEG (2), 0%, 0.1 µg/106 vp. 
c P3= PLL (4–15), PEG (5), 10%, 0.025 µg/106 vp.  
 
Particle size and zeta potential of PLL-g-PEG-FlAd 
Particle size and surface charge values of the selected PLL-g-PEG-FlAd vectors were 
measured by DLS and are listed in Table 2.6.  
Table 0.6: Mean particle size of NtAd, FlAd, and PLL-g-PEG-FlAd vectors formed at parameters 
found to give optimum transduction efficiency. 
Vector 
Mean particle size 
± standard deviation (nm) 
Zeta potential 
± standard deviation (mV) 
NtAd 108 ± 2.2 -21.3 ± 0.5 
FlAd 115 ± 3.4 -17.7 ±1.5 
PLL15-30-g0.5-PEG25% (S1) 193 ± 3.9 11.2 ± 4.2 
PLL4-15-g5-PEG5% (S2) 270 ± 6.4 7.5 ± 1.2 
2.4 DISCUSSION 
Adenoviral vectors have been widely used in gene therapy [23]. Despite having many 
benefits, Ad also has limitations [155]. Cellular uptake of Ad is dependent on the presence of 
CAR on the target cell surface because the fiber knob domain of the virus binds to this receptor. 
However, many cells including cancer cells have down regulated CAR which limits the ability of 
Ad-based vectors to infect those cells [158, 201, 202]. A promising strategy to overcome this 
obstacle is chemical or physical modification of the Ad surface with polymers to alter the native 
tropism of the virus [203]. In the present study, we used a fiberless Ad (FlAd) that was previously 
generated in our lab to overcome the native tropism problem [184]. However, fiber truncation 
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resulted in a reduction in the ability of the virus to enter CAR-positive or CAR-negative cells. To 
restore the transduction efficiency of the virus in a CAR-independent way, we constructed an 
FlAd hybrid vector, in which the negatively charged FlAd surface was physically coated with the 
cationic PLL-g-PEG copolymer via electrostatic interaction. PEG grafted PLL has been widely 
used for non-viral gene delivery [191, 204, 205] but have been of limited use with viral vectors 
and have not been comprehensively studied [134].  
As measured by DLS, the increase in the particle size of PLL-g-PEG-FlAd relative to 
FlAd, indicated that FlAd was coated with PLL-g-PEG copolymer. Zeta potential is an important 
factor for the cellular uptake as well as the stability of the complex. The zeta potential of the FlAd 
was -17.7 ±1.5 mV, due to the negatively charged amino acids in the virus hexon proteins [134, 
206, 207]. Upon complexing with copolymer, hybrid vectors showed a positive zeta potential. 
Formation of hybrid vectors was further verified by TEM microscopy as shown in Figure 2.3. 
TEM images of FlAd demonstrated the characteristic hexon structure and the icosahedral shape 
of the virus particle. In contrast, the hybrid vector had a rough surface structure with a coat of 
copolymer surrounding the virus particles. Particles that are formed by charge interactions with 
cationic polymers are prone to aggregation, leading to variability and instability. However, TEM 
imaging revealed that hybrid vectors retained their original shape with no aggregations. This 
might be due to the charge repulsion of the virus surface yielding a stable vector without 
significant aggregation. These data collectively demonstrate that the negatively charged FlAd was 
adequately complexed with the cationic PLL-g-PEG copolymer to form a stable hybrid 
adenoviral vector. 
Transduction is a process by which DNA is introduced into a cell by a virus or a viral 
vector. The efficiency of the virus in infecting the cells is measured by the level of the reporter 
gene expression (lac-Z gene in the Ad we are using) which is called transduction efficiency (TE). 
The positive charge of the copolymer can enhance the virus gene transfer in a CAR-independent 
pathway. In this study, we demonstrated that PLL-g-PEG have replaced the function of the fiber 
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and have resulted in the formation of PLL-g-PEG- FlAd with an increased transduction efficiency 
in both CAR-positive and CAR-negative expressing cells. 
The optimum MOI required to achieve a good transduction efficiency of hybrid vectors is 
important to be determined. Low MOI results in poor gene expression, whereas, high MOI often 
results in reduced cell viability. Also, MOI is cell specific and needs to be adjusted according to 
each cell type. As expected, the infectivity of the FlAd was low at smaller values of MOI and did 
not improve significantly even as the MOI was increased in both cell types. The infectivity of 
PLL-g-PEG-FlAd vectors was higher than FlAd at all MOIs tested suggesting that the vectors can 
effectively transduce the cells in a CAR-independent way. MOI of 100 and 250 infectious virus 
particles per cell showed the best transduction efficiency of hybrid vectors in HEK 293 and NIH 
3T3 cells, respectively.  
Formulation parameters including: PLL Mwt, PEG Mwt, degree of PEGylation and ratio 
of copolymer to virus, has been recognized as important factors that affect the physicochemical 
characteristics of the formed vectors and consequently their gene delivering efficiency [134, 136, 
207]. Hence, a library of PLL-g-PEG copolymer with variation in PLL Mwt (1–5, 4–15, 15–30, 
30–70, and 70–150 kDa), PEG Mwt (0.5, 2, 5, and 10 kDa), degree of PEGylation (5, 10, 25, 30, 
and 40%), was synthesized to prepare PLL-g-PEG-FlAd vectors to be used at 0.001–1 µg PLL-g-
PEG /106 virus particles (vp).  
Afterwards, the formulation parameters were varied one at a time to define the range of 
factors/levels that is required for an efficient gene delivery. The molecular weight of PLL 
affected the physicochemical characteristics and hence the gene delivery efficiency of the vectors. 
PLL-g-PEG-FlAd prepared with high Mwt PLL (70-15 kDa) showed a very poor transduction 
efficiency (Figure 2.5). High Mwt PLL induced crosslinking between the virus particles that 
resulted in the formation of large sized particles (>1µm) with reduced infectivity (Figure 2.9). 
Besides, cells infected with those vectors showed low cell viability owing to the cytotoxic 
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cationic nature of the polymer (Data not shown) [143]. Therefore, the 70-150 kDa PLL was 
excluded from further studies.  
PEGylation is a popular modification that can reduce the cytotoxicity associated with 
PLL complexes, immunogenicity of the virus as well as increase the vector circulation times and 
prolong the transgene expression [124, 195]. However, PEGylation compromises the ability of 
the virus to interact with cell receptors, which reduces the transduction of Ad in cells [20]. Hence, 
PEG molecular weight and degree of PEGylation (DOP) must be balanced to gain the benefits 
while not sacrifice the TE. Hybrid vectors prepared with high Mwt PEG (10 kDa) showed the 
lowest transduction efficiencies among other vectors prepared with lower Mwts of PEG (Figure 
2.6). This poor transduction efficiency is due to the increased shielding effect of the PEG 
molecules and the decreased accessibility of the positively charged PLL molecules to interact 
with the cell membrane for better binding and internalization. Zhang et al. have shown that the 
longer the PEG chain, the more PEG shielding effect and thus the lower the gene transfer 
efficiency [207]. The other important factor related to using PEG is the DOP of the copolymer. 
The lower number of PEG substitution on the PLL backbone (DOP) might be insufficient for the 
stabilization of the virus particles, whereas the higher number of PEG substitution could retard 
the internalization of the excessively PEGylated virus particles into the cells [134, 205]. Hybrid 
vectors showed high transduction efficiency up till 25% DOP, however, transduction efficiency 
dropped upon increasing the DOP to 30% and 40% (Figure 2.10). This might be attributed to 
three reasons. First, as the DOP increases, a transition of the PEG from the “mushroom” coil to 
the “brush” shape occurs [208]. As a result of the higher PEG shielding, fewer positive charges 
are exposed for electrostatic binding of the vector to the cells. Previous studies have explained 
that copolymers with few PEG blocks showed improved gene transfer efficiency compared to 
those with relatively more PEG blocks [205, 207]. Second, the brush-mushroom coil effect also 
resulted in the formation of larger particle size of PLL-g-PEG-FlAd vectors (Figure 2.10). For 
example, the particle size of vectors increased from 134 to 335 nm and from 190 to 295 nm upon 
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increasing the DOP from 5% to 40% when prepared with PLL (1–5) and (15–30 kDa), 
respectively. Third, the zeta potential values decreased upon increasing the DOP as demonstrated 
in Figure 2.11. The decrease in the surface charge of the vectors is directly correlated to the 
instability of the vectors as well as their tendency to aggregate and form larger sized particles 
[209]. This data collectively led us to exclude high Mwt PEG (10 kDa) and high DOP (30% and 
40%) to complete our study.  
The effect of PLL-g-PEG/FlAd ratio is the last factor studied. The transduction efficiency 
of hybrid vectors did not increase until the PLL-g-PEG/FlAd ratio reached 0.001 µg/106 vp. Very 
low ratios of PLL-g-PEG molecules to FlAd particles (0.0001 and 0.00001 µg/106 vp) were 
insufficient to coat the virus for better attachment and cellular internalization which might have 
led to the poor transduction efficiency observed. As the amount of PLL-g-PEG increased; the 
copolymer mediated better TE. However, an excess amount PLL-g-PEG/FlAd > 1 µg /106vp did 
not improve gene expression in both cell types. A high ratio of cationic copolymer to virus 
particle led to larger particle sized (Figure 2.9) and decreased surface charge vectors (Figure 
2.11). Both effects might have prevented efficient viral infection [188]. Besides, high 
concentrations of cationic polymers are known to be toxic to cells [210]. Hence, a range of 
0.001–1 µg /106 vp was used to prepare hybrid vectors for further studies. 
We have covered a screening for the factors and ranges that affect the transduction 
efficiency in both CAR-positive and CAR-negative cells. In that step, we have used a one factor 
at a time (OFAT) experiment, where we varied one factor at a time to be able to conduct the 
study. OFAT experiments have been widely used for studying the factors affecting the gene 
delivery efficiency of different viral and non-viral vectors [38, 151, 211, 212]. Nevertheless, 
previous researchers have studied a limited number of factors with this kind of experiments. In 
contrast, Design of Experiments (DOE) statistical methodology permits the simultaneous 
evaluation of multiple factors effect on experimental performance and the analysis of their 
interactions in order to find their optimal combinations [213]. We have used DOE to facilitate the 
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exploration of that broader range of parameters combinations, which improved the prediction of 
the response. DOE has been primarily used in industry to optimize processes and maximize their  
robustness, but recently DOE has also been applied in biomedical research to different types of 
analyses, as determination of the best cell media composition and the optimization of cell 
transfection [214].  
Two quadratic models were generated by the two investigated designs, one for CAR-
positive (HEK 293) and the other for CAR-negative (NIH 3T3) cell. The transduction efficiency 
in each cell line (response) was fitted to the quadratic model and the adequacy of these models 
was verified using ANOVA test (Table 2.4). The R2 values indicated that the model explained 
99.4% and 99.5% of the variability of the transduction efficiency of PLL-g-PEG-FlAd vectors in 
HEK 293 and NIH 3T3 cells around the mean, respectively. Adequate precision measures the 
signal to noise ratio which is the range of a predicted response relative to its associated error. A 
ratio greater than 4 is desirable to qualify the model to be used to navigate the design space. The 
ratios were 25.7 and 35.7 for responses 1 and 2, respectively, indicating the adequacy of the two 
models in navigating hybrid vectors transduction efficiency space. 
In order to characterize an analytical method as robust, it must be able to predict 
responses with small differences from to the experimental data. Thus, the validity of models was 
evaluated by experimentally preparing and measuring the transduction efficiency of hybrid 
vectors in three chosen random check points (Table 2.5). The actual results obtained, together 
with their predicted values generated from the equations for the D-optimal quadratic models 
showed a good agreement between the actual and predicted responses. The obtained biases 
ranged between 2.5% and 18.2% and agreements below 30% bias were considered acceptable 
[215]. These findings confirm the predictability of the D-optimal model and suggest the 
possibility of its utilization for the optimization of the transduction efficiency of PLL-g-PEG-
FlAd vectors in HEK 293 and NIH 3T3 cells.  
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DOE allowed us to optimize the PLL-g-PEG-FLAd vector to achieve maximum TE, 
where we selected one hybrid vector for each cell type with the highest desirability. In CAR- 
positive and CAR-negative cells, PLL15-30-g25%-PEG0.5 (S1) and PLL4-15-g5%-PEG5 (S2) at 1 µg 
PLL-g-PEG /106 vp were selected as they achieved 3.5 and 10.2 folds of transduction efficiency 
compared to FlAd, respectively. The results suggest that hybrid vectors chosen have benefited 
from a combination of different factors and levels to reach the optimum TE. S1 hybrid vector was 
composed of PLL (15–30 kDa) that resulted in a positive zeta potential of 11.2 mV, but yet a 
reasonable particle size of 193 nm. High Mwt PLL based particles are expected to form large 
sized particles but adding short PEG chains (0.5 kDa) at high DOP (25%) offered a steric 
hindrance in-between the particles ensuring their stability. At the same time, the short PEG chains 
allowed for a good exposure of the positively charged PLL molecules coating the virus which 
enabled cellular binding and internalization. S2 hybrid vector was composed of PLL (4–15 kDa) 
which also resulted in a positive zeta potential of 7.5 mV, but a particle size of 270 nm. A larger 
particle size and a lower surface charge is expected upon using long PEG chains (5 kDa). 
Although the PEG chains on the PLL backbone might have shielded the virus surface but using it 
at a low DOP (5%) offered enough flexibility for the PEG chains to move freely to expose the 
positive charged PLL molecules for better binding and cellular internalization.  
The differences in-between the vectors’ composition that achieved high transduction 
efficiency was expected as we are infecting different cell types. Although hybrid vectors formed 
are CAR-independent, the transduction efficiency seems to depend on the cell type. Both HEK 
293 and NIH 3T3 cells have different cell membrane fluidity and elasticity characteristics which 
affect the endocytosis of nanoparticles [216, 217]. In addition, HEK 293 is an epithelial human 
kidney cell while the NIH 3T3 is a mouse fibroblast cell and they use different endocytic 
mechanisms that would call for different characteristics of nanoparticles [218, 219]. Further 
studies and investigations are required to confirm these hypotheses, but we have covered some of 
the endocytic pathways differences as later explained in chapter 4. 
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2.5 CONCLUSION 
This work showed that complexes of FlAd with cationic copolymer to form PLL-g-PEG-
FlAd hybrid vectors enhanced the efficiency of gene expression in vitro. The function of the fiber 
of adenovirus in mediating good transduction efficiency was replaced by the physical 
modification of the virus with PLL-g-PEG copolymer. The physicochemical properties as well as 
the efficiency of gene expression of PLL-g-PEG based vectors depended on several factors, 
including PLL Mwt, PEG Mwt, DOP, and the amount of copolymer/virus. Hybrid vectors 
showed good gene expression in a CAR-independent way. Therefore, these vectors may increase 
gene transfer to different cell types irrespective of CAR. In this study, hybrid vectors were 
optimized to increase their transduction efficiency in specific cell types and results cannot be 
generalized to all cells. Considering the effect of cell type on the vector gene expression 
efficiency is essential when vectors are designed to be used in vivo in other cell types. With 
improvement in the gene delivering efficiency of the vectors, it may be possible to deliver lower 
concentrations of the vector and thus reduce toxicity and any associated adverse effects with the 
use of high viral dose. The subsequent increase in the therapeutic index would further improve 





HYBRID ADENOVIRAL VECTORS OVERCOMING ADENOVIRUS LIMITATIONS: 
IMMUNOGENICITY, SERUM STABILITY, AND TROPISM 
3.1 INTRODUCTION 
An efficient yet safe and non-toxic gene delivery vector is a necessity in the field of gene 
therapy research. Adenovirus (Ad) is among the most widely used vectors for gene therapy [220]. 
Ad can transduce a broad range of cells including dividing and non-dividing cells and produce 
high levels of gene transfer relative to other currently available vectors [162, 221-223]. Despite 
its advantages, Ad gene delivery vectors suffer from serious limitations like immunogenicity and 
promiscuous tropism. Shortly after systemic administration of Ad vectors, pathogen-associated 
molecular patterns (PAMPs) such as capsid, fiber, or DNA of the virus activate an inflammatory 
response. This results in the release of cytokines/chemokines such as interleukin-6 and interleukin 
-12 (IL-6, IL-12) and tumor necrosis factor (TNFα), and Interferon gamma-induced protein 10 
(IP-10) causing the activation of an innate immune response [101, 163, 224, 225]. The elicited 
innate immune response leads to the rapid clearance of the Ad vector from the body before the 
desired therapeutic response is achieved [72, 226].  
Previous researchers have attempted to reduce the immunogenicity of adenovirus vectors 
through genetic or chemical/physical modification. Ablation of Coxsackievirus Adenovirus 
Receptor (CAR) (primary receptor), αv integrin binding (secondary receptor), and heparan sulfate 
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glycosaminoglycan (HSG) (third receptor) binding have been reported to reduce liver toxicity and 
IL-6 production [227]. Chemical /physical modification was also accomplished through coating 
or conjugating the vector to polyethylene glycol (PEG), poly-N-(2-hydroxy propyl) 
methacrylamide (pHPMA), poly(ethylenimine) (PEI), poly (L-lysine) (PLL), and chitosan [188, 
194, 203, 228, 229]. PEGylation is the most popular approach to shield the surface of the vector 
from aggregation, opsonization, and phagocytosis, reducing liver biodistribution, as well as 
weakening the immune responses and prolonging the circulation time of the vector [39, 228, 
230]. Not only PEGylation has addressed the immunogenicity of the virus but PEGylation was 
also used to manage viral tropism problem. Ad cellular attachment primarily depends on the 
ubiquitously found CAR, which results in widespread infection of many cell types [61]. 
Dependency on this receptor also limits the ability of Ad-based vectors to transform cells that 
lack CAR, such as advanced tumor cells, peripheral blood cells, vascular smooth muscle cells, 
and cancer cells where CAR is down-regulated. PEGylation reduces adenovirus transduction 
efficiency in CAR-positive or CAR-negative cells through non-specific steric hindrance [231, 
232]. This simultaneous ability to reduce immunogenicity and lower transduction efficiency in 
cells is known as the “PEG dilemma” [196]. To solve this dilemma, researchers have investigated 
the use of cationic polymers such as PEI and PLL to complement the function of PEGylation and 
increase adenovirus transduction efficiency [12,27]. These polymers carry highly positive 
charges, allowing them to coat the anionic adenovirus particles. This strategy usually improves 
transduction efficiency but also increases cytotoxicity, as observed when coating adenovirus with 
high-molecular-weight PEI or PLL [203]. Therefore, a good balance between PEG Mwt, degree 
of PEGylation, PLL Mwt, and PLL-g-PEG/FlAd ratio can ameliorate the cytotoxicity of the 
vector. The charged particles can easily interact with serum proteins when systemically 
administrated [24, 25]. This interaction would reduce the distribution of the vectors in vivo 
resulting in rapid clearance from the body.  
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In this chapter, we combine the two approaches of removing the fiber of Ad with the 
PLL-g-PEG coating to address the aforementioned problems in the gene delivery. We selected the 
PLL-g-PEG-FlAd vectors with the highest transduction efficiency from chapter 2 to examine 
their immunogenicity, toxicity, serum stability, and transduction in CAR-low and CAR-negative 
cells. 
3.2 MATERIALS AND METHODS 
Cell culture 
Mouse fibroblast cell line (NIH 3T3), and human embryonic kidney cell line (HEK 293), 
Chinese hamster ovary (CHO), and breast cancer cell line (MCF-7) were purchased from the 
American Type Culture Collection (ATCC) (Manassas, VA). The HEK 293, CHO, and MCF-7 
were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS) (Mediatech, Inc., Manassas, VA). The NIH 
3T3 cells were cultured in DMEM with 10% calf serum (CS) (Mediatech, Inc., Manassas, VA). 
Cells were maintained in a humidified atmosphere at 37ºC and 5% CO2. 
Adenovirus 
Recombinant adenovirus type 5 (Ad) encoding lacZ reporter gene and lacking the E1 and 
E3 native genes was generated from the native adenoviral plasmid, pAdEasy-1(Addgene plasmid 
16400) and pShuttle-CMV-lacZ (Agilent, CA) [197, 198]. The virus was amplified in HEK 293 
cells and purified using ion-exchange chromatography in a Vivapure Adenopack purification kit 
following the manufacturer’s protocol (Sartorius Stedim, CO). Ad was concentrated and stored in 
phosphate-buffered saline (PBS), pH 7.4. The number of virus particles (vp) was determined by 
measuring UV absorbance at 260 nm (1 U ≈ 1012 virus particles/ml) [198].  
Fiberless Adenovirus generation 
A FlAd plasmid (pAd5-FlAd) was generated using homologous recombination to remove 
the fiber gene from the native Ad plasmid (pAdEasy-1) [184]. Since the removal of the fiber 
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severely reduced the infectivity of the virus, amplification of FlAd is required in 633 cell line that 
stably expresses fiber protein. Transfection of 633 cells with pAd5-FlAd produced a virus with 
fiber protein but lacking the fiber gene. Passaging the virus on 633 cells enriched the virus titer. 
The enriched virus was then used to produce FlAd through a final passage on HEK 293 cells. The 
virus was collected and purified using the Vivapure Adenopack purification kit following the 
manufacturer’s protocol (Sartorius Stedim Arvada, CO). The virus was quantified by measuring 
the absorbance of the viral DNA at a wavelength of 260 nm (1 U ≈ 1012 virus particles/ml).   
FlAd is unable to infect cells since it lacks the fiber protein. While generally the virus is 
referred to as infectious particles, it is better to think about the particles as being potentially 
infectious. Not all NtAd or FlAd particles, however, are infectious or potentially infectious. 
Mittereder et al. showed that only about 5% of adenovirus particles are infectious [199]. The 
other 95% of the virus particles are thought to be inactive due to harsh conditions the viral 
particles go through during the purification steps. An assumption made in the present study was 
that only 5% of FlAd is potentially infectious.  
PLL-g-PEG copolymer synthesis 
 PLL-g-PEG was synthesized via reacting the primary amines (-NH2) on the lysine chains 
of PLL-HBr (Sigma, Aldrich) with the succinimidyl ester group on the mPEG-NHS (Creative 
PEGworks, NC). For these studies, we prepared, PLL15-30-g25%-PEG0.5 and PLL4-15-g5%-PEG5 to 
use in preparing hybrid viral vectors to transduce the cells, respectively. PLL15-30-g25%-PEG0.5-
FlAd was prepared by adding 14 mg of 0.55 kDa mPEG-NHS to 15 mg of 15-30 kDa PLL-HBr 
dissolved in 200 µl of phosphate-buffered saline (PBS). PLL4-15-g5%-PEG5 was prepared by 
adding 25 mg of 5 kDa mPEG-NHS to the dissolved 15-30 kDa PLL-HBr. The mixtures were 
allowed to react for 2 hours before being washed with ultrapure water in a 10 kDa centrifugal 
concentrator. After 3 washes, each grafted copolymer was lyophilized and stored at -20°C.  
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Formation of PLL-g-PEG-FlAd vectors  
PLL-g-PEG-FlAd vectors were prepared through electrostatic attraction between the 
positively charged copolymer and the negatively charged FlAd). PLL-g-PEG was dissolved in 
PBS, pH 7.4, prior to the dropwise addition of the virus so that the concentration of PLL-g-PEG 
was 1 µg/106vp. Subsequently, the solution was mixed by gentle aspiration with the pipet tip and 
allowed to incubate for 10–30 min at room temperature before further use.  
Evaluation of the innate immune response of PLL-g-PEG-FlAd vectors in-vitro  
To evaluate the effect of modified Ad on the innate immune response, the amount of pro-
inflammatory cytokines, interleukin 6 (IL-6), and tumor necrosis factor (TNFα), produced by 
murine macrophage RAW 264.7 cells were measured. Raw 264.7 cells were seeded 18–24 hours 
before transduction in 12-well plates at a seeding density of 2 × 105 cells/well. The cells were 
treated with NtAd, FlAd and PLL15-30-g25%-PEG0.5-FlAd and PLL4-15-g5%-PEG5-FlAd vectors for 
32 hours at a MOI of 100. The cell-free supernatants were then collected and the levels of IL-6 
and TNFα were then quantified using an IL-6 and a TNFα ELISA kit (BD Biosciences, Sparks, 
MD) following the manufacturer’s protocols. Briefly, ELISA plates precoated with monoclonal 
antibodies against murine IL-6 or TNFα were used. Fifty microliters of IL-6 standards and 
samples were incubated on the pre-coated plates for 2 h at room temperature. The plates were 
washed and biotinylated anti-mouse IL-6 antibodies, together with streptavidin–HRP conjugates 
were added for another hour. The plates were again washed, and TMB One-Step reagent was 
added for 30 min. The reactions were stopped with 50 µl of 2 N H2SO4. The amount of IL-6 and 
TNFα was determined by measuring absorbance at 450 nm and compared to a standard curve 
with known IL-6 and TNFα concentration, respectively. 
Effect of serum on transduction efficiency of PLL-g-PEG-FlAd 
 The transduction efficiency of Ad, FlAd, and PLL-g-PEG-FlAd vectors was studied on 
HEK 293 and NIH 3T3 cells. Cells were seeded for 24 hours before infection at 5 × 104 cells per 
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well in 24 well plates. The cell culture medium was replaced with serum-free DMEM at 50% of 
the typical well culture volume (for example, 0.5 ml in a 12-well plate). The cells were then 
infected with the virus or hybrid viral vector using a MOI of 100 for HEK 293 cells and 250 for 
NIH 3T3 cells. Four hours later, the medium was again replaced with fresh cell culture medium 
containing 10%, 20%, 30%, 40% or 50% of serum, and cells were incubated for 48 hours. LacZ 
expression was quantified using the chemiluminescence based Beta-Glo assay (Promega Inc., 
Madison, WI). The reporter gene expression was measured in terms of relative light units (RLU) 
with a Lumat LB9507 luminometer (EG&G, Berthold, Bundoora, Australia). The gene 
expression was then normalized to total cellular protein determined using the bicinchoninic acid 
assay (BCA assay) (Pierce, Rockford, IL). All gene expression results were normalized to the 
infectivity in serum free medium. 
Cytotoxicity of PLL-g-PEG-FlAd vectors 
 Cytotoxicity of PLL-g-PEG-FlAd vectors was measured using a Cell Titer-Blue® Cell 
Viability assay (Promega, Madison, WI). HEK 293 and NIH-3T3 cells were seeded in 96-well 
plates for 18–24 hours at 2 × 104 cells/well. Before transduction, the growth medium on the cells 
was replaced with fresh growth medium. PLL15-30-g25%-PEG0.5-FlAd and PLL4-15-g5%-PEG5-FlAd 
were prepared and added to HEK 293 and NIH 3T3, respectively and incubated for 48 hours at 37 
°C and 5% CO2. Cell Titer-Blue® Reagent was added to each well following manufacturer’s 
protocol. Twenty µl of CellTiter-BlueTM reagent was added to each well 24 h after the addition 
of drugs. The cells were incubated further for 1– 4 h at 37°C. Fluorescence at 560/590 nm was 
measured in a SpectraMax Gemini XPS spectrophotometer (Molecular Devices, Sunnyvale, CA).  
Transduction of PLL-g-PEG-FlAd in CAR-low and CAR-negative cells 
The transduction efficiency of Ad, FlAd, and PLL-g-PEG-FlAd vectors was studied on 
MCF-7 (CAR-low), NIH 3T3, and CHO (CAR-negative) cells. MCF-7 and CHO cells were 
grown in DMEM with10% FBS, while NIH 3T3 cells were grown in DMEM with 10% CS. All 
cells were maintained at 37ºC in a humidified 5% CO2 incubator. Cells were seeded for 24 hours 
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before infection at 5 × 104 cells per well in 24 well plates. The cell culture medium was replaced 
with serum-free DMEM at 50% of the typical well culture volume (for example, 0.25 ml in a 24-
well plate). The cells were then infected with the virus or hybrid viral vector using a MOI of 250 
and 500 for the three cell lines. Four hours later, the medium was again replaced with fresh cell 
culture medium (containing serum), and cells were incubated for 48 hours. LacZ expression was 
quantified using the chemiluminescence based Beta-Glo assay (Promega Inc., Madison, WI). The 
reporter gene expression was measured in terms of relative light units (RLU) with a Lumat 
LB9507 luminometer (EG&G, Berthold, Bundoora, Australia). The gene expression was then 
normalized to total cellular protein determined using the bicinchoninic acid assay (BCA assay) 
(Pierce, Rockford, IL). All gene expression results were normalized to the infectivity of the 
unmodified virus. 
Statistical analysis  
All statistical analyses mentioned in this study were done using the ANOVA 
analysis followed by a post-ad-hoc test. A result was deemed not significant (ns) if p > 0.05. 
(#p < 0.05; ##p < 0.01; ###p < 0.001; *p< 0.0001). 
3.3 RESULTS  
Innate immune response 
The systemic administration of Ad vectors initiates cytokine induction in innate effector 
cells such as dendritic cells, macrophages, or peripheral blood mononuclear cells [72]. This innate 
immune response limits the effectiveness of Ad vectors for gene therapy [18]. We assessed the 
levels of pro-inflammatory cytokines, IL-6, and TNFα, produced by macrophage RAW 264.7 
cells to evaluate the innate immune response of PLL-g-PEG-FlAd hybrid vectors compared to 
NtAd, FlAd reduced the elicited IL-6 and TNFα production by 60% and 15%, respectively, due 
to removing the fiber protein. Modification of FlAd with PLL-g-PEG showed a 20–30% further 
reduction in IL-6 production and a 40–45% further reduction in TNFα compared to FlAd. Upon 
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comparing our hybrid vectors to NtAd, RAW 264.7 cells produced 80 pg/ml of IL-6 after 
exposure to NtAd and only 26 and 23 pg/ml after exposure to PLL15-30-g25%-PEG0.5-FlAd (S1) and 
PLL4-15-g5%-PEG5-FlAd (S2) vectors, respectively (Fig. 3.1A). Similarly, RAW 264.7 cells 
produced 542 pg/ml of TNFα after exposure to NtAd and this value was reduced to 246 and 277 
pg/ml after exposure to PLL15-30-g25%-PEG0.5-FlAd (S1) and PLL4-15-g5%-PEG5-FlAd (S2) vectors, 
respectively (Figure 3.1B).  
 
 
Figure 3.31: Expression of inflammatory cytokine (A) IL-6 and (B) TNFα produced by RAW 
264.7 macrophage cells upon exposure to NtAd, FlAd, PLL15-30-g25%-PEG0.5-FlAd (S1) and PLL4-


























































Effect of serum on the transduction efficiency of PLL-g-PEG-FlAd vectors 
Serum proteins can easily interact with gene delivery vectors and inhibit their 
transduction in cells [211, 233]. For efficacious systemic gene delivery, the delivery system has 
to resist these non-specific interactions with serum. To examine the effect of serum on the 
transduction efficiency of PLL-g-PEG-FlAd, vectors were incubated in the presence and absence 
of up to 50% serum, since serum constitutes 50% (v:v) of blood [234]. Figure 3.2 shows that 
NtAd and FlAd lost ~45% and 55% of their efficiency when subjected to 50% serum in both cell 
lines. In contrast, the transduction efficiency of PLL-g-PEG-FlAd hybrid vectors decreased only 
by a range of 15-20% in the presence of 50% serum. These results indicate that there is a 
decreased possibility of the vector binding to serum protein allowing improved blood circulation 





Figure 3.3: Transduction Efficiency NtAd, FlAd, PLL15-30-g25%-PEG0.5-FlAd (S1), and PLL4-15-
g5%-PEG5-FlAd (S2), at 1 µg /106vp in the presence of 0-50% serum in (A) HEK 293, (B) NIH 
3T3. Y-axis – Normalized transduction efficiency to the same expression at 0% serum for every 
tested vector. X-axis – Serum (%) in transduction media.  
Cytotoxicity of PLL-g-PEG-FlAd vectors 
PLL-g-PEG is biodegradable and hence is more desirable to use as a cationic component 
in gene delivery vectors compared to other polymers like PEI or PLL [235]. We investigated the 
cytotoxicity of hybrid vectors prepared with PLL-g-PEG compared to those prepared with PEI or 
PLL using an assay of cellular metabolic activity (Cell-Titer Blue TM) on HEK 293 and NIH 3T3 








































































lines decreased to 16% and 36% in HEK 293 and NIH 3T3 cells, respectively (Figure 3.3A). In 
contrast, vectors prepared with PLL-g-PEG had lower cytotoxicity as the cell viability was 
maintained >85% in both cell lines (Figure 3.3B). These results suggest that PLL-g-PEG-FlAd 
hybrid vectors have a good safety profile that enables them to be used at higher concentrations if 
needed in vivo.  
  
Figure 3.3A: Cytotoxicity of PLL15-30-FlAd, and PEI25-FlAd and PLL15-30-g25%-PEG0.5-FlAd (S1) 




Figure 3.3B: Cell viability of HEK 293 and NIH 3T3 cells when incubated with PLL4-15-g5%-













































Transduction efficiency of PLL-g-PEG-FlAd across a panel of CAR-low and CAR-
negative cell lines 
Ad infection depends primarily on the binding of the virus fiber to CAR [61]. Ad 
was reported to have a variable ability to infect different CAR-negative cell lines like cancer 
cells where CAR are downregulated [201, 236-238]. Therefore, we chose CAR-low cells 
like human breast cancer cells (MCF-7) and CAR-negative cells like NIH 3T3 and Chinese 
hamster ovary (CHO), to study the requirement for a CAR-mediated binding event in 
adenovirus infection.  
 
Figure 3.3: Transduction efficiency of the PLL-g-PEG-FlAd in CAR-deficient cells. NIH 3T3, 
CHO, or MCF7 cells were transduced with NtAd, FlAd, PLL-g-PEG-FlAd at a MOI of 250. 
PLL15-30-g25%-PEG0.5-FlAd (S1), PLL4-15-g5%-PEG5-FlAd (S2), PLL1-5 g25%-PEG2-FlAd (S3), and 
PLL1-5-g10%-PEG5-FlAd (S4) at 1 µg /106vp was used. Results were normalized to RLU/µg total 
protein of FlAd (Relative Light Units per µg total protein in cellular lysate). Relative transduction 
efficiency of PLL-g-PEG-FlAd to FlAd was expressed as a fold increase relative to FlAd. Data 
represent the means and standard deviations of triplicate experiments. #-p < 0.0001, ***-p<0.001, 
**-p<0.01, *-p<0.05 versus FlAd. 
To compare the gene transfer effect of PLL-g-PEG-FlAd in different cell lines, we 
measured the transduction efficiency in MCF-7, NIH 3T3, and CHO cells. Cells were transduced 
at a MOI of 250 of NtAd, FlAd or PLL-g-PEG-FlAd, and the transduction efficiency was 






































As shown in Figure 3.4, the transduction efficiency of PLL-g-PEG-FlAd was 
significantly greater than that for FlAd in all cell lines. Interestingly, hybrid vectors’ transduction 
in NIH 3T3, CHO, and MCF-7 reached 10.2, 4.4 and 20-folds compared to FlAd. The variable 
transduction of PLL-g-PEG-FlAd in CAR-deficient cells demonstrates their ability to transduce a 
broader range of cells.  
3.4 DISCUSSION 
A major obstacle in gene therapy is the shortage of efficient, non-toxic, non-
immunogenic gene delivery agents. Having demonstrated that our adenoviral vectors improved in 
vitro transduction efficiency through ablating CAR binding with the removal of Ad fiber and 
replacing its function with cationic PLL-g-PEG copolymer. Since fiber removal and PEG reduces 
immune response and transduction, while PLL and PEG worsen serum stability and cytotoxicity, 
it was necessary to assess hybrid vectors' immunogenicity, serum stability, and cytotoxicity as 
well as its ability to transduce CAR-deficient cells.  
The innate immune response is a barrier to the effective application of Ad vectors in 
humans [154]. Systemic administration of Ad rapidly recruits macrophages, inducing secretion of 
pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor (TNFα) [72, 
225]. To understand how the removal of Ad fiber proteins and modification with the PLL-g-PEG 
copolymer affects the innate immune response, RAW 264.7 macrophage cells were incubated 
with NtAd, FlAd and our selected hybrid vectors (S1 and S2 ), then IL-6 and TNF α cytokine 
production was quantified using an ELISA assay. Macrophages produced 15% and 60% lower 
levels of IL-6 and TNF α when incubated with FlAd compared to NtAd (Figures 3.1). This may 
be due to the absence of fiber protein-receptor interaction, which triggers a cascading effect on 
the innate immune system [129]. The knob of the fiber was reported to be necessary for 
adenoviral uptake in macrophages via the scavenger receptor A [239]. Modification of FlAd with 
electrostatically bound PLL-g-PEG reduced the secretion of IL-6 and TNFα by almost 70% and 
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50% compared to NtAd, respectively. This reduction may be due to PEG shielding the epitopes 
on the virus capsid from macrophage uptake and activation [126, 129]. Previous studies have also 
shown a significantly lower secretion of the proinflammatory cytokines IL-6 and TNFα after 
delivery of PEGylated vectors [124, 126, 194, 203]. Higher Mwt PEG (5 kDa), used in preparing 
PLL4-15-g5%-PEG5-FlAd (S2) hybrid vector, showed a more significant effect in reducing the 
immune response compared to lower Mwt PEG (0.5 kDa) used in preparing PLL15-30-g25%-PEG0.5-
FlAd (S1) vectors. PEG (5 kDa) resulted in a 15% and 11% reduction in IL-6 and TNFα secretion 
compared to PEG (0.5 kDa), respectively. This might be due to the lower efficiency of higher 
Mwt PEG in transducing macrophages [240]. 
An efficient gene delivery vector in vivo must also be stable under physiological 
conditions. The presence of serum is known to inhibit transductions of most gene delivery 
vectors, particularly charged species that can easily interact with the serum proteins [241, 242]. 
This serum interaction decreases the circulation of the vectors in the blood resulting in rapid 
clearance of the vectors from the body. Consequently, these undesired interactions should be 
minimal to deliver the required genes before the vectors are cleared out of the body. We tested the 
transduction efficiency of our hybrid vectors in comparison to NtAd in the presence of up to 50% 
serum in transduction media. NtAd and FlAd transduction efficiency was maintained at 10% 
serum then decreased to 56% and 45% at 50% serum compared to serum-free conditions, 
respectively. In contrast, PLL-g-PEG-FlAd showed better serum stability, where the transduction 
efficiency only decreased to a range of 80–85 % in the presence of 50% serum. PEG shields the 
surface of vectors due to its hydrophilic nature where PEG forms a hydrated cloud that sterically 
precludes vectors from interacting with neighboring vectors and/or blood components [243, 244]. 
The interaction of vectors with serum and their circulation time in vivo is controlled by different 
factors, like PEG molecular weight (Mwt), PEG surface density, and the charge of the vectors 
[243]. Recently, Yang and coworkers reported that when the grafting density is "high" PEG with 
a Mwt as low as 559 Da can effectively shield surfaces of 100 nm polystyrene (PS) NPs [54]. 
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Thus, grafting lower Mwt PEG (550 Da) at a higher PEGylation ratio (25%) as in hybrid vector 
(S1) may be similarly effective in stabilizing the vectors as grafting higher Mwt PEG (5kDa) at 
lower PEGylation ratio (5%) in hybrid vector (S2). Both S1 and S2 vectors showed a 20% and 15% 
decrease in transduction efficiency upon incubation in 50% serum, respectively. Last, we cannot 
neglect the effect of the particle charge on the stability of the vectors in serum. The positive 
surface charge of hybrid vectors formed a steric hindrance against interaction with anionic serum 
proteins, leading to more stabilization of the vectors.  
PEG contributed to the lower immunogenicity and the better serum stability of hybrid 
vectors; however, PEG might have affected the transduction efficiency of cells. Cationic 
polymers were combined to Ad to enhance the gene transfer into cells. PEI is a cationic polymer 
of good transfection efficiency, however, PEI is well known for its toxicity [245]. Upon binding 
to FlAd, a 64% and 84% reduction in cell viability of HEK 293 and NIH 3T3 cells was observed, 
respectively. PLL is a cationic polymer of lower cytotoxicity compared to PEI. This explains why 
the cell viability of HEK 293 and NIH 3T3 cells decreased by only 10% and 20% n respectively, 
when subjected to PLL-FlAd. To ameliorate the cytotoxicity of PLL, PEG was conjugated to PLL 
to form a more biocompatible and biodegradable copolymer. The results of the cytotoxicity of 
PLL-g-PEG-FlAd showed a low level of cytotoxicity that was similar to NtAd alone where the 
cell viability exceeded 85% with all hybrid vectors.  
The variable level of CAR expression on cells is another major limitation that inhibits 
effective Ad delivery in vitro and in vivo due to the dependence of Ad infection on CAR binding 
[33]. Cationic polymers can enhance Ad-mediated gene transfer and infection through CAR-
independent pathways. In this chapter, combined with chapter 2 findings, we demonstrated that 
hybrid vectors enhanced transduction efficiency in cells regardless of the CAR expression level. 
The transduction efficiency of the FlAd coated with PLL-g-PEG was significantly increased 
where it reached 20, 4.4, and 10 folds in both CAR-low (MCF-7) and CAR-negative (CHO and 
NIH 3T3) expressing cells compared to FlAd, respectively. Enhanced transduction efficiency of 
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PLL-g-PEG-FlAd was more evident in CAR-low than CAR-negative cells. Previous studies also 
showed that gene expression levels in MCF-7 (CAR-low) was more profound compared to that in 
HT1080 or C2C12 (CAR-negative) cells after transduction with polymer-modified Ad complex 
[246]. Another study has shown that the fold increase in gene transfer efficiency of polymer based 
adenoviral vector was inversely correlated to the level of CAR expression in cancer cells [136]. 
These data lead to the conclusion that cationic copolymers can improve the gene transfer 
efficiency of Ad to cells with variable CAR expression taking advantage of the surface charge of 
the vector. 
3.5 CONCLUSION 
In this chapter, we demonstrated that the PLL-g-PEG-FlAd hybrid vectors previously 
selected for their high transduction efficiency showed lower cytotoxicity and better serum 
stability than NtAd in vitro. The vectors have also evoked a weaker innate immune response as 
we have seen lower cytokine production amid macrophage incubation with the vectors. These 
effects are likely because the PEG chains masked the epitopes on the Ad surface from the 
surrounding environment. The vectors were able to transduce efficiently CAR-deficient cell lines 
like NIH 3T3, MCF-7, and CHO, proving their potential to deliver genes to different cell lines 
with poor CAR expression. Given these results, the removal of the fiber protein combined with 
viral surface modification with PLL-g-PEG can be anticipated as an effective way to further 





INTRACELLULAR TRAFFICKING OF HYBRID ADENOVIRAL VECTORS 
 
4.1 INTRODUCTION 
In earlier chapters, we discussed the design of PLL-g-PEG-FlAd hybrid vectors. Ad 
has been engineered by removing the virus fiber and replacing its function with a synthetic 
PLL-g-PEG copolymer. This modification affected the physicochemical properties of 
hybrid vectors as well as their transduction efficiencies. The intracellular trafficking of 
hybrid vectors is also expected to be modulated by this modification. In this chapter, we 
describe the different cellular mechanisms leading to different transduction efficiencies of 
hybrid vectors in HEK 293 cells and NIH 3T3 cells.  
The intracellular trafficking pathway of Ad serotype C, type 5 (Ad5) is demonstrated in 
Figure 4.1. Ad5 binds via its fiber knob to Coxsackie and Adenovirus Receptor (CAR), a 46 kDa 
cell receptor abundant in human tissues [61, 247, 248]. CAR binding is followed by secondary 
interactions of the RGD motifs in the virus penton base proteins with αvß3 or  αvß5 integrins in 
the cells to initiate endocytosis and viral entry [62]. In addition to the classical CAR binding and 
the RGD-interaction, Ad might use alternative entry pathways like heparan sulfate proteoglycans 
(HSPGs) as receptors [62] and lactoferrin as a bridge between viral particles and the cell surface 
[249].
83 
Once bound to the cell surface, the virus enters the cell by clathrin-mediated endocytosis 
[250]. Endocytosis appears to be rapid, as up to 30% of bound Ad is internalized within 15 
minutes [62]. After the clathrin-coated pit separates from the plasma membrane as an endocytic 
vesicle, vacuolar H+-ATPase acidifies the endosomes. This acidification triggers conformational 
changes in the adenovirus capsid exposing the lytic factor identified as protein VI [251]. The 
protein VI facilitates the escape of the partially uncoated Ad particles from the early endosomes 
to be released into the cytosol before being degraded by lysosomal proteases [251-253]. After 
escaping to the cytosol, Ad particles are rapidly (30-60 min) translocated along microtubules to 
the nucleus via dynein motor protein to accumulate at the nuclear periphery and then docks at the 
nuclear pore complex [254-256]. Biochemical analysis has indicated that the majority of the viral 
capsid remains in the cytoplasm and is gradually dismantled by a combination of step-wise 
dissociation and proteolytic degradation [257]. Finally the liberated viral genome enters the 
nucleus via nuclear pores to be stored as an episome [258, 259]. Once in the nucleus, viral genes 
are expressed and ultimately result in the generation of transgene products.  
 
Figure 4.1: Infection pathway of adenovirus. The fiber protein of the virus binds to CAR, the 
Penton base binds to integrin which promotes clathrin mediated endocytosis. After cellular 
internalization, the virus capsid undergoes conformational changes and escapes the endosome to 
bind to microtubule/dynein for transport across the nucleus. The virus disassembles and releases 
the viral gene close to the nuclear pore to be taken up by the nucleus. 
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Gene delivery vectors tend to deliver their cargo into the cells via two key pathways: 
endocytic pathways or non-endocytic pathways [260]. Fusion and penetration are amongst the 
non-endocytic mechanisms, but this capability is possessed by only a few vectors; typically 
vectors with an associated fusogenic peptide or penetrating peptide which our current design of 
hybrid vectors lacks. Endocytic pathways have been known as the primary transport mechanisms 
for both viral and non-viral vectors into cells [261]. Endocytosis includes three major types: 
clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis (CavME), and 
macropinocytosis (MP). The clathrin-mediated endocytosis depends on the formation of coated 
pits through the assembly of the protein clathrin and other adapter proteins enveloping the 
endocytic vesicles [262]. These small coated pits (approximately 100 nm in diameter) can uptake 
particles up to 200 nm [263], and form a vesicle after endocytosis, later maturing into late 
endosomes and fusing with lysosomes. In contrast, caveolae are small flask-shape invaginations 
of the plasma membrane that resemble the shape of a cave (hence the name caveolae) [261]. 
Caveolae consist of the cholesterol-binding protein caveolin with a bilayer enriched in cholesterol 
and glycolipids. The size of a particle that is internalized by caveolae-mediated endocytosis 
ranges from 200 nm to 500 nm [263]. Macropinocytosis refers to the fusion of ruffling plasma 
membranes which enfold surrounding fluids within 0.5–5 µm vesicles. The filling of the vesicles 
occurs in a non-specific manner and results in pinosomes that travel into the cytosol and fuses 
with other vesicles such as endosomes and lysosomes [264]. 
Endocytosis differs according to the cell type and characteristics of the endocytosed 
particles such as size and type of material [263, 265-267]. Studies have reported that cationic 
polymer-based gene delivery vectors enter cells via clathrin-dependent, as well as clathrin-
independent endocytosis, caveolae-mediated endocytosis, and macropinocytosis [136, 267-270]. 
The major obstacle to efficient gene delivery is generally believed to be failure of endosomal 
escape, leading to vector degradation in lysosomes. Depending on the synthetic part of the hybrid 
85 
vector, different escape mechanisms from the endosomal compartment have been proposed. 
These include endosomal membrane destabilization [268, 271], free polymer-mediated membrane 
permeability and nanoscale hole formation [272], and endosomolysis caused by osmotic swelling 
[273, 274]. PLL does not have the ability to mediate a proton sponge effect like PEI leading to 
lower transduction of polyplexes compared to PEI-based polyplexes [275].  
The purpose of our study was to examine the effect of replacing the virus fiber with PLL-
g-PEG copolymer on the intracellular trafficking pathways. We wanted to investigate whether 
there is any difference in internalization and intracellular trafficking of our hybrid vector 
compared to the native adenovirus and whether these differences affect intracellular fate and 
transduction efficiency. Our experiments were based on a fibreless adenovirus that avoids CAR 
receptor binding as the first step in cell trafficking. We hypothesized that our hybrid vectors bind 
to the negatively charged components on the cell membrane. Next, we investigated the trafficking 
mechanisms of our hybrid vectors PLL15-30-g25%-PEG0.5-FlAd (S1) in CAR-positive (HEK 293) 
cells and PLL4-15-g5%-PEG5-FlAd (S2) in CAR-negative (NIH 3T3) cells via cellular uptake and 
transductions studies in the presence of various drug inhibitors that would affect specific 
pathways within the cell. We hypothesized that replacing the virus fiber with a synthetic 
copolymer would affect the hybrid vector internalization and trafficking pathways relative to the 
virus. 
4.2 MATERIALS AND METHODS 
Cell culture 
Mouse fibroblast cell line (NIH 3T3), and human embryonic kidney cell line (HEK 293) 
were purchased from the American Type Culture Collection (ATCC) (Manassas, VA). The HEK 
293 was cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL, Grand Island, 
NY) supplemented with 10% fetal bovine serum (FBS) (Mediatech, Inc., Manassas, VA). The 
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NIH 3T3 cells were cultured in DMEM with 10% calf serum (CS) (Mediatech, Inc., Manassas, 
VA). Cells were maintained in a humidified atmosphere at 37ºC and 5% CO2. 
Adenovirus 
Recombinant adenovirus type 5 (Ad) encoding lacZ reporter gene and lacking the E1 and 
E3 native genes were generated from the native adenoviral plasmid, pAdEasy-1 (Addgene 
plasmid 16400) and pShuttle-CMV-lacZ (Agilent, CA) [197, 198]. The virus was amplified in 
HEK 293 cells and purified using ion-exchange chromatography in a Vivapure Adenopack 
purification kit following the manufacturer’s protocol (Sartorius Stedim, CO). Ad was 
concentrated and stored in phosphate-buffered saline (PBS), pH 7.4. The number of virus 
particles (vp) was determined by measuring UV absorbance at 260 nm (1 U ≈ 1012 virus 
particles/ml) [198].  
Fiberless Adenovirus generation 
A FlAd plasmid (pAd5-FlAd) was generated using homologous recombination to remove 
the fiber gene from the native Ad plasmid (pAdEasy-1) [184]. Since the removal of the fiber 
severely reduced the infectivity of the virus, amplification of FlAd is required in 633 cell line that 
stably expresses fiber protein. Transfection of 633 cells with pAd5-FlAd produced a virus with 
fiber protein but lacking the fiber gene. Passaging the virus on 633 cells enriched the virus titer. 
The enriched virus was then used to produce FlAd through a final passage on HEK 293 cells. The 
virus was collected and purified using the Vivapure Adenopack purification kit following the 
manufacturer’s protocol (Sartorius Stedim Arvada, CO). The virus was quantified by measuring 
the absorbance of the viral DNA at a wavelength of 260 nm (1 U ≈ 1012 virus particles/ml).   
FlAd is unable to infect cells since it lacks the fiber protein. While generally the virus is 
referred to as infectious particles, it might be better to think about the particles as being 
potentially infectious. Not all NtAd or FlAd virus particles, however, are infectious or potentially 
infectious. Mittereder et al. showed that only about 5% of adenovirus particles are infectious 
[199]. The other 95% of the virus particles are thought to be inactive due to harsh conditions the 
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viral particles go through during the purification steps. An assumption made in the present study 
was that only 5% of fiberless Ad is potentially infectious.  
PLL-g-PEG copolymer synthesis 
 PLL-g-PEG was synthesized via reacting the primary amines (-NH2) on the lysine chains 
of PLL-HBr (Sigma, Aldrich) with the succinimidyl ester group on the mPEG-NHS (Creative 
PEGworks, NC). For these studies, we prepared, PLL15-30-g25%-PEG0.5 and PLL4-15-g5%-PEG5 to 
use in preparing hybrid vectors to transduce HEK 293 and NIH 3T3 cells, respectively. PLL15-30-
g25%-PEG0.5 was prepared by adding 14 mg of 0.5 kDa mPEG-NHS to 15 mg of 15–30 kDa PLL-
HBr dissolved in 200 µl of phosphate-buffered saline (PBS). PLL4-15-g5%-PEG5 was prepared by 
adding 25 mg of 5 kDa mPEG-NHS to the dissolved 15-30 kDa PLL-HBr. The mixtures were 
allowed to react for 2 hours before being washed with ultrapure water in a 10 kDa centrifugal 
concentrator. After 3 washes, each grafted copolymer was lyophilized and stored at -20°C.  
Formation of PLL-g-PEG-FlAd hybrid vector  
PLL-g-PEG-FlAd hybrid vectors were prepared through electrostatic attraction between 
the positively charged copolymer and the negatively charged FlAd. PLL-g-PEG was dissolved in 
PBS, pH 7.4, prior to the dropwise addition of the virus so that the concentration of PLL-g-PEG 
was 1 µg/ 106vp. Subsequently, the solution was mixed by gentle aspiration with the pipet tip and 
allowed to incubate for 10–30 min at room temperature before further use.  
Transduction efficiency studies 
The transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd hybrid vectors was 
studied on HEK 293 and NIH 3T3 cells. Cells were seeded for 24 hours before infection at 5 × 
104 cells per well in 24 well plates. The cell culture medium was replaced with serum-free 
DMEM at 50% of the typical well culture volume (for example, 0.5 ml in a 12-well plate). The 
cells were then infected with the virus or hybrid viral vector using a MOI of 100 for HEK 293 
cells and 250 for NIH 3T3 cells. Four hours later, the medium was again replaced with fresh cell 
culture medium (containing serum), and cells were incubated for 48 hours. LacZ expression was 
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quantified using the chemiluminescence based Beta-Glo assay (Promega Inc., Madison, WI). The 
reporter gene expression was measured in terms of relative light units (RLU) with a Lumat 
LB9507 luminometer (EG&G, Berthold, Bundoora, Australia). The gene expression was then 
normalized to total cellular protein determined using the bicinchoninic acid assay (BCA assay) 
(Pierce, Rockford, IL). All gene expression results were normalized to the infectivity of the 
unmodified virus. 
qPCR assay for quantitation of Ad cellular uptake  
DNA isolation.  Total cellular DNA was purified using DNeasy Blood and Tissue Kit 
(Qiagen, Valencia, CA, USA), following the manufacturer’s protocol. Total DNA was eluted in a 
final volume of 50 µl, aliquoted, and stored in -20°C until quantitation by qPCR assay. 
Primer design and HRM melting predictions.  Nucleic acid sequences used to design 
primers for Ad (AC-000008.1), HEK 293, and NIH 3T3 were retrieved from NCBI. For Ad, 
primers were designed using the consensus gene region of E2 gene in Primer 3 (v.4.0.0)[276, 
277]. The HRM melting temperature (HRM Tm) of the expected PCR product was predicted with 
uMELT SM [278]. To serve as an internal control, Beta-actin (ACTB) primer pair for either HEK 
293 or NIH 3T3 was designed. Primers generated for the virus were then uploaded to the NCBI 
Primer BLAST database to predict in silico primer specificity. 
Gradient PCR assays.  To determine the optimal annealing temperature for each primer 
pair, 20 µl PCR reactions were performed as follows: 10 µl GoTaq (Promega, Madison, WI), 6 µl 
nuclease-free water, 2 µl of each forward and reverse primer (10 µM), and 2 µl of DNA. The 
thermocycler conditions for each reaction were as follows: four minutes at 95°C, 40 cycles of 20 
seconds at 95°C, 20 seconds at a 50–62°C gradient, 20 seconds at 72°C, followed by a final 
extension for four minutes at 72°C. PCR was performed in a gradient capable Biometra 
Thermocycler (Biosciences, Dublin, Ireland). PCR products were then visualized using gel 
electrophoresis with SYBR™ Safe stain (Invitrogen, Carlsbad, CA) and visualized in a Gel 
Doc™ XR+ (Biorad, Hercules, CA). 
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qPCR reaction mix and reaction conditions.  The optimized master mix (20 µl) was 
comprised of 10.5 µl of Hot Start master mix (Thermofisher, Waltham, MA), 5 µl nuclease-free 
water, 1 µl of each 10 µM forward and reverse primer, 1 µl LC Green (BioFire, Salt Lake City, 
UT), and 1 µl of DNA. PCR was performed in a Corbett Research Rotorgene (QIAGEN, Hilden, 
Germany) and the thermocycler profile used was 95°C for 4 minutes, 40 cycles of 95°C for 20 
seconds, 55°C for 20 seconds, 72°C for 20 seconds, followed by a final extension of 72°C for 5 
minutes, and an HRM ramping from 50°C to 90°C, increasing by 0.25°C every second. The 
concentration of purified Ad was measured using PicoGreen® dsDNA quantitation assay, 
following the manufacturer’s protocol [279, 280]. Six-fold dilution from 1 ng to 1 fg/µl was 
prepared to generate a standard calibration curve by plotting Ct against each concentration. For 
comparison of results of drug-treated versus untreated samples, the livak method (ΔΔCt) was used 
(Appendix II).  
Binding and internalization studies 
HEK 293 and NIH 3T3 cells were seeded 24 h before transduction at 105
 
cells/well in 12-
well plates. Cells and plates were transferred to 4 °C for 30 min before growth media containing 
serum was replaced with serum-free DMEM. Viral samples, NtAd, FlAd, or PLL-g-PEG-FlAd, 
were immediately added to the samples and cells were incubated for 1 hr on ice to halt 
endocytosis. Before measuring the amount of bound virus, unbound viruses were removed by 
washing the cells with cold trypsin followed by cold PBS. The cells were then scraped and 
pelleted by centrifugation. Viral and cellular DNA were isolated, and qPCR was used to measure 
viral titer, which was normalized to the housekeeping gene ACTB.  
To measure the amount of internalized virus, unbound viruses were first removed by 
rinsing with cold trypsin followed by cold PBS. Warm growth medium was then added to the 
cells, which were transferred to an incubator at 37°C. After incubation at 37°C for 4 h, the cells 
were scraped and pelleted by centrifugation. Cellular DNA was isolated, and qPCR was used to 
quantify viral titer (as explained before), which was normalized to the housekeeping ACTB gene.  
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Drug cytotoxicity and compatibility studies  
 The toxicity of drugs was determined using the Cell Titer- BlueTM Cell Viability 
Assay. HEK 293 and NIH 3T3 cells were seeded in a 96-well plate at 2–2.5 x 104 cells/well 24 h 
before the addition of drugs. Different concentrations of drugs were added to the cells in a serum-
free medium and left for 4 h before the medium was replaced with complete media. Twenty µl of 
CellTiter-BlueTM reagent was added to each well 24 h after the addition of drugs. The cells were 
incubated further for 1–4 h at 37°C. Fluorescence at 560/590 nm was measured in a SpectraMax 
Gemini XPS spectrophotometer (Molecular Devices, Sunnyvale, CA).  
Competitive heparin assay  
HEK 293 and NIH 3T3 cells were plated in a 12-well plate for 24 hours, then media was 
replaced with DMEM and treated with heparin (100 µg/mL) for 1 h at 37ºC. Either NtAd or PLL-
g-PEG-FlAd was then added to the cells and incubated for 24–36 h. The transduction efficiency 
was measured as mentioned before and data were compared to untreated controls. 
Drug inhibitor-based trafficking studies (Transduction)  
 HEK 293 and NIH 3T3 cells were seeded 24 h before transduction at 105
 
cells/well in 12-
well plates. Growth media containing serum was replaced with serum-free DMEM along with the 
addition of predetermined concentrations of drugs. After 1 h of incubation with drugs, NtAd, 
FlAd, or hybrid vectors were added dropwise. The transduction media was replaced again with 
complete media 4 h post-transduction. Transduction efficiency was measured 48 h post-
transduction as mentioned above. 
Drug inhibitor-based trafficking studies (Cellular uptake)  
 HEK 293 and NIH 3T3 cells were seeded 24 h before transduction at 105
 
cells/well in 12-
well plates. Growth media containing serum was replaced with serum-free DMEM along with the 
addition of predetermined concentrations of drugs. After 1 h of incubation with drugs, NtAd, 
FlAd, or hybrid vectors were added dropwise. The cells were washed with PBS containing 
0.001% SDS 4 h post-transduction to remove surface-bound, uninternalized vectors. Cells were 
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then washed twice with room temperature PBS and harvested by scraping into PBS, centrifuging 
at 100 × g for 4 minutes at 4°C, and resuspending in PBS. 
Statistical analysis 
All statistical analyses mentioned in this study were done using the ANOVA analysis 
followed by a post-ad-hoc test. A result was deemed not significant (ns) if p > 0.05. (# p < 0.05; 
## p < 0.01; ### p < 0.001; * p< 0.0001).  
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4.3 RESULTS  
The role of heparan sulfate proteoglycans in vector transduction 
Ad5 primarily binds to CAR via its fiber protein, followed by secondary interactions of 
the virus penton base protein with αv integrins on the cell [62]. Heparan sulphate proteoglycans 
(HSPGs) are also involved in the binding of Ad5 as receptors [281, 282]. Since we are studying a 
fiberless adenovirus, CAR interactions do not appear to be the key mechanism for cell binding. 
An alternative cell surface interaction, however, is the electrostatic attraction between vector 
cations and highly anionic cell surface proteoglycans. We wanted to verify that our hybrid vector 
interacts with HSPGs and uses them as receptors to bind to the cells. We treated HEK 293 (CAR-
positive) and NIH 3T3 cells (CAR-negative) cells with heparin to competitively bind to HSPGs. 
In HEK 293 cells, heparin decreased the transduction efficiency of PLL-g-PEG-FlAd by 50%, 
while no inhibitory effect on the transduction of NtAd was observed. In contrast, the addition of 
heparin reduced transduction of NIH 3T3 by NtAd and PLL-g-PEG-FlAd by 30% and 58%, 
respectively (Figure 4.2).  
 
Figure 4.2: Transduction efficiency of A) NtAd and hybrid vector S1 (PLL15-30-g25%-PEG0.5-
FlAd) in HEK 293 cells and B) NtAd and hybrid vector S2 (PLL4-15-g5%-PEG5-FlAd) in NIH 3T3 
cells after treating both cell lines with heparin. Y-axis – Normalized RLU/µg total protein = 
Relative Light Units per µg total protein in cellular lysate normalized to the same expression for 








































Binding and internalization studies  
We measured the binding and internalization of PLL-g-PEG-FlAd to investigate whether 
the lower level of transduction efficiency observed for PLL-g-PEG-FlAd in HEK 293 and NIH 
3T3 cells (compared to NtAd) was caused by low levels of binding and/or inefficient 
internalization of the vector.  
The binding amount of the virus/ hybrid vector was determined by halting the 
endocytosis of the virus/hybrid vector at low temperature, followed by removal of unbound virus 
then quantitation of the remaining bound virus/hybrid vector to the cell membrane. The 
internalized amount was then compared to the respective amount of the virus/hybrid vector bound 
to the cell membrane. The binding and internalization of FlAd and PLL-g-PEG-FlAd on HEK 
293 cells (CAR-positive) were lower compared to that of NtAd (Figure 4.A). In CAR-positive 
(HEK 293) cells, removal of the fiber and knob protein decreased the binding of the virus to only 
17% compared to the native virus. Although, not able to completely restore cell binding, addition 
of the copolymer significantly improved the cell binding to 76%.  FlAd showed good 
internalization results where all of the virus bound to the cells was internalized inside. While 63% 
of the bound hybrid vectors were internalized inside the cells. The same study was carried in 
CAR-negative (NIH 3T3) to investigate the relatively high level of transduction efficiency 
observed for PLL-g-PEG-FlAd compared to NtAd or FlAd. Hybrid vectors showed a 55-fold 
increase in binding levels compared to NtAd and FlAd that barely bound to the cells (Figure 4.B). 
In contrast, at least 80% of the NtAd, FlAd, and the hybrid vector cell bound particles were 






Figure 4.3: (1) Binding (A) and internalization (B) of NtAd, FlAd, and PLL15-30-g25%-PEG0.5-
FlAd in HEK 293 cells, (2) Binding (A) and internalization (B) of NtAd, FlAd, PLL4-15-g5%-
PEG5-FlAd in NIH 3T3 cells. In (A) Binding results are normalized to NtAd values. In (B) 
Internalization results are normalized to the respective binding values of each vector. *p<0.05, 















































































































Effect of pharmacological inhibitors on cellular uptake and transduction efficiency of NtAd, 
FlAd, and PLL-g-PEG-FlAd hybrid vectors 
Determining the optimal concentration of drug inhibitors.  The use of pharmacological 
inhibitors is a well-known method to study the intracellular trafficking mechanisms of drug and 
gene delivery vectors [260]. These drugs inhibit specific intracellular pathways leading to 
modified trafficking mechanisms and/or shut down of the pathway which would be observed in 
the decrease in the transduction efficiency. By studying the results of the various inhibitions, a 
map for the trafficking of hybrid vectors through the cells would be designed. 
These drug inhibitors, however, are cytotoxic beyond certain concentrations and can 
affect the transgene expression via non-specific mechanisms [283]. Therefore, the drug inhibitors 
cytotoxicity was studied to optimize the concentration to be used in HEK 293 and NIH 3T3 cells. 
The optimal concentration was decided based on the highest drug concentration that resulted in > 
90% cell viability.  
Table 4.1 summarizes the mechanism of the action of the drugs on intracellular 
trafficking as well as the concentration for their optimal use to study their inhibitory effect. 
Table 4.1: Mechanism of action and optimal concentration of drug inhibitors 
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10 μg/ml [285] 
Genistein  
(GST) 
Inhibition of tyrosine kinase 
preventing caveolae formation 
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0.1 μg/ml [286] 
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endosomal vesicles inhibiting release 
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caveolae formation and 
macropinocytosis (CavMe,MP) 
0.1 μg/ml [289] 
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Figure 4.4: Cytotoxicity on HEK 293 cells after exposure to different concentrations of drug 
inhibitors (CPZ, AMD, GST, CCD, and CLC). Y-axis – % Cell viability, X-axis – 
Concentration (μg/ml).  
 
Figure 4.5: Cytotoxicity on NIH 3T3 cells after exposure to different concentrations of drug 
inhibitors (CPZ, AMD, GST, CCD, and CLC). Y-axis – % Cell viability, X-axis – 






















































Figure 4.6: Cytotoxicity on HEK 293 and NIH 3T3 cells after exposure to different 
concentrations of Bafilomycin A1 (BAF). Y-axis – % Cell viability, X-axis – Concentration 
(nM).  
 
Development of qPCR assay method for the quantitation of viral DNA  
Primer design and HRM melting predictions. Three primer pairs were designed, one for 
Ad E2 gene and two ACTB primers as housekeeping / internal control genes for HEK 293 and 
NIH 3T3 cells. All three primers are capable of being used in end-point PCR, qPCR, and HRM. 
Table 4.2 compiles thermodynamic features of designed primer sequences such as annealing 
temperature (Tm), predicted amplicon melting point (HRM Tm), oligo self-complementary score 
(Any), and oligo 3′ self-complementarity at the 3´ termini (3′). Primers for Ad E2 gene amplify 
a segment of 194 bp of Ad genome. Primers for ACTB-HEK 293 and ACTB-NIH 3T3 amplify a 
























Table 4.2: Primer sequences for Ad E2 primers and the two ACTB housekeeping genes primers 
along with the corresponding thermodynamic values calculated by Primer 3 (v.0.4.0) for each.  
 Target Primer 
Primer Sequence  













































59.07 3 0 
*The thermodynamic metrics listed include primer annealing temperature (Tm), amplicon size 
(Size) predicted amplicon melting point (HRM Tm), oligo self-complementary score (Any), and 
oligo 3′ self-complementarity at the 3´ termini (3′). 
 
Gradient PCR assays. Primers designed for Ad and the internal control genes 
successfully amplified their respective expected products, which matched predicted lengths. 
Gradient PCR was used to assess the optimal annealing temperature of each designed primer pair 
(Figure 4.7).Each of the primer pairs performed according to optimal thermodynamic values in 
Table 4.2. The annealing temperatures studied ranged from 50−62 °C, producing a clear, bright 
PCR product of the predicted length. When used to amplify NtAd or FlAd, the primer pair 
produced lower DNA yields when used at annealing temperatures above 60 °C as determined by 
visual assessment of DNA yields. 55°C was chosen as an annealing temperature as it showed 
bright, clear bands for all sets of primers. 
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Figure 4.7: Gradient PCR of each primer pair and target template for Ad- E2, ACTB-HEK 293, 
ACTB-NIH 3T3 from 50 to 62 °C. Gel electrophoresis was performed on a 2% agarose gel in 0.5 
x TAE at 95 V for approximately 45 min, alongside a 100 bp ladder (New England Biolabs, 
Ipswich, MA). 
 
qPCR reaction mix and reaction conditions. A standard calibration curve was developed 
by measuring the quantity of purified FlAd in a serial dilution from 1 ng to 1 fg/µl. As shown in 
Figure 4.8.A each serial dilution generated separated real-time reactions with distinct threshold 
cycle values (Ct). The correlation coefficient (R2) for the line is 0.995 with an efficiency of 1.02 
(Figure 4.8C). This plot is then used as a calibration curve for extrapolating relative expression 
levels of E2 gene in unknown experimental samples. Absolute quantification of samples was used 
for determining binding and internalization levels of virus or hybrid vectors. Relative 
quantification of samples using the livak method (ΔΔCt) was used for comparing the cellular 
uptake of virus or hybrid vectors in untreated and drug inhibitor-treated cells. The relative 
quantification calibration curve results were normalized to that of a housekeeping gene in the 
same sample, and then the normalized numbers are compared between samples.  
High-Resolution Melting Analysis (HRM) is a recently developed technique for fast, 
high-throughput post-PCR analysis of genetic mutations or variance in nucleic acid sequences. 
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After completion of the PCR step, the amplified target is gradually denatured by increasing the 
temperature in small increments, to produce a characteristic melting profile; this is termed 
melting analysis. The amplified target denatures gradually, releasing a specialized dye, which 
results in a decrease in fluorescence. HRM curve shows differentiation in the rates at which PCR 





Figure 4.8: qPCR standard curve. A) A representative amplification plot, B) HRM df/dT melting 
curve, and C) a standard curve is shown. A six-fold serial dilution of purified Ad, ranging from 1 
ng to 1 fg/µl, was used to generate both plots.  
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Cellular internalization mechanism of the hybrid vector (PLL-g-PEG-FlAd) in CAR-
positive cells (HEK 293) and CAR-negative cells (NIH 3T3) 
A hybrid viral vector is a promising tool for gene therapy approaches. Analyzing the 
vector internalization and trafficking pathways within the cell is crucial nowadays. This is 
especially essential when comparing to viral vectors that benefit from their inherent high cell 
transduction efficiency. Understanding uptake mechanisms and intracellular pathways of the 
vector will lead to improvement in the design of hybrid vectors for further applications. 
We studied the cellular uptake of PLL-g-PEG-FlAd in CAR-positive (HEK 293) and 
CAR-negative (NIH 3T3) cells. The cellular uptake of NtAd and FlAd served as effective 
controls for elucidating the changes that occur in the trafficking mechanism due to the presence 
of the copolymer (PLL-g-PEG) as a synthetic part that functions in place of the fiber of the virus.  
Clathrin-, caveolin-, and macropinocytosis- mediated pathways are proposed to be the 
main routes of endocytosis for viral vectors [261, 292]. To assess the role of these three endocytic 
pathways in the entry of PLL-g-PEG-FlAd hybrid vectors, each pathway was blocked by a 
specific drug inhibitor. Chlorpromazine is known to block clathrin-mediated internalization [284], 
while genistein inhibits tyrosine kinase preventing caveolae dependent pathway [293], and 
amiloride is used to inhibit the macropinocytosis [294] by preventing the induction of membrane 
ruffling. 
The cellular uptake of the virus and hybrid vectors in HEK 293 cells in the presence of 
inhibitors of clathrin- or caveolae- or macropinocytosis mediated uptake is represented in figure 
4.9A. The cellular uptake of NtAd decreased significantly (to 30%) when clathrin-mediated 
endocytosis was blocked by CPZ (p<0.0001). The uptake of the virus was also reduced (to 60%) 
when macropinocytosis was blocked by AMD (p<0.0001). This data is consistent with the major 
role of clathrin-mediated endocytosis and the minor role of macropinocytosis in the 
internalization of Ad [295]. The same effect was shown with the cellular uptake of FlAd, where 
the uptake decreased to 60% (p<0.01) and 40% (p<0.0001) after treating cells with CPZ and 
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AMD, respectively. For PLL-g-PEG-FlAd, the uptake was significantly reduced to 60% (p<0.05) 
when either clathrin or macropinocytosis pathways was blocked. We observed that neither the 
cellular uptake of the virus nor the hybrid vector was affected upon treating the cells with GST, as 
caveolin was not reported to be a pathway for internalization of Ad. 
As the cellular uptake is not indicative of gene expression, gene expression experiments 
in the presence of the same drug inhibitors were performed. As shown in Figure 4.9B, CPZ 
significantly reduced the transduction efficiency of NtAd and FlAd, to 35% and 45% (p<0.0001), 
respectively. Similarly, CPZ caused a 50% (p<0.0001) reduction in the transduction efficiency of 
PLL-g-PEG-FlAd. Interestingly, pre-treatment with AMD inhibited the gene expression of PLL-






Figure 4.3: A) Cellular uptake and B) transduction efficiency of NtAd, FlAd, and PLL15-30-g25%-
PEG0.5-FlAd in the presence of drug inhibitors in HEK 293 cells. Y-axis – Normalized values of 
the virus or hybrid vector normalized to the same uptake for untreated cells. X-axis – Drugs at 









































































Since cellular trafficking is cell dependent, we studied the internalization mechanism of 
PLL-g-PEG-FlAd in CAR-negative (NIH 3T3) cells. The cells were treated with the same drug 
inhibitors to block the three endocytic pathways, clathrin, caveolar, and macropinocytosis 
mediated endocytosis. The cellular uptake of PLL-g-PEG-FlAd hybrid vector was measured and 
compared to that of NtAd as represented in Figure 4.10A. The cellular uptake of NtAd decreased 
to 42% (p<0.001) and to 22% (p<0.0001) when clathrin-mediated endocytosis and 
macropinocytosis were blocked by CPZ and AMD, respectively. The uptake of PLL-g-PEG-
FlAd, in contrast, was diminished by the clathrin- and caveolae-mediated endocytic drug 
inhibitors to 47%, and 65%, respectively. The transduction efficiency was also studied as 
demonstrated in Figure 4.10B. The transduction efficiency of NtAd decreased to 45% (p<0.0001) 
and 81% (p<0.01) after using clathrin- and macropinocytosis mediated endocytosis drug 
inhibitors, respectively. While the transduction efficiency of PLL-g-PEG-FlAd decreased to 55% 
(p<0.0001), and 75%(p<0.01) after treating the cells with clathrin- and caveolar-mediated 




Figure 10: A) Cellular uptake and B) transduction efficiency of NtAd, and PLL4-15-g5%-PEG5-
FlAd in the presence of drug inhibitors in NIH 3T3 cells. Y-axis – Normalized values of the virus 
or hybrid vector normalized to the same uptake for untreated cells. X-axis – Drugs at optimal 


































































Endolysosomal escape of the hybrid vector (PLL-g-PEG-FlAd) in CAR-positive cells (HEK 
293) and CAR-negative cells (NIH 3T3) 
After internalization of the hybrid vector into endosomes, the hybrid vector must escape 
the endosomal vesicles to be released into the cytoplasm before being degraded by the lysosomal 
proteases. A drop in pH is concomitant with the escape of Ad from the endocytic vesicle. Yet, the 
precise role of pH in virus disassembly is under investigation [296]. The cellular uptake and the 
transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd in the presence of BAF were 
studied in HEK 293 cells as shown in Figure 4.11A and B, respectively. The cellular uptake of 
either the virus or the hybrid vector was unaffected when BAF was used as this drug does not 
affect internalization, rather it inhibits the acidification of endosomes. To investigate whether the 
endosomal acidification is required for transduction of PLL-g-PEG-FlAd vectors, BAF was added 
to the cells prior to their transduction by hybrid vectors. The transduction efficiencies of hybrid 
vectors were compared to that of NtAd and FlAd under the same conditions. Figure 4.11B shows 
that the transduction efficiency of NtAd was significantly decreased (to 65%) (p<0.0001), while 
that of FlAd was further reduced (to 38%) (p<0.0001. In case of PLL-g-PEG FlAd, the 
transduction efficiency decreased to almost the same level as NtAd (to 65%). This indicates that 
low-pH endosomal processes are essential for the productive transduction of the virus and hybrid 
vectors. 
The effect of acidification inhibition on the endosomal escape of PLL-g-PEG-FlAd 
vectors in CAR-negative (NIH 3T3) cells was also studied. No significant change in the cellular 
uptake of NtAd or PLL-g-PEG-FlAd was noticed upon treating the cells with BAF as represented 
in Figure 4.12A. However, BAF inhibited the acidification of endosomes in NIH 3T3 cells which 
lead to a reduction in the transduction efficiency of NtAd and PLL-g-PEG FlAd to 79% (p<0.01) 
and 30% (p<0.0001), respectively (Figure 4.12B). 
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Figure 4.11: A) Cellular uptake and B) transduction efficiency of NtAd, and PLL15-30-g25%-
PEG0.5-FlAd in the presence of Bafilomycin (BAF) in HEK 293 cells. Y-axis – Normalized 
values of the virus or hybrid vector normalized to the same uptake for untreated cells. X-axis – 
Drugs at optimal concentrations. * p<0.05, **p<0.01, ***p<0.001, #p<0.0001.  
 
  
Figure 4.12: A) Cellular uptake and B) transduction efficiency of NtAd, and PLL4-15-g5%-PEG5-
FlAd in the presence of Bafilomycin (BAF) in NIH 3T3 cells. Y-axis – Normalized values of the 
virus or hybrid vector normalized to the same uptake for untreated cells. X-axis – Drugs at 


























































































































Intracellular trafficking of the hybrid vector (PLL-g-PEG-FlAd) in CAR-positive cells 
(HEK 293) and CAR-negative cells (NIH 3T3) 
After endosomal escape, the virus/hybrid vector is released into the cytosol to complete 
its journey to deliver the transgenes to the nucleus. To be transported across the cytoplasm, 
particles can interact with the cytoskeletal network including the microtubules and/or actin 
filaments to be directed towards the nucleus. The cellular uptake and the transduction efficiency 
of NtAd, FlAd, and PLL-g-PEG-FlAd were studied in HEK 293 cells after disruption of the 
microtubules or the actin filaments with CLC or CCD, respectively (Figure 4.13A and B). Upon 
treating the cells with CLC, no significant change in the cellular uptake of NtAd, FlAd or PLL-g-
PEG-FlAd was observed as this drug does not affect their internalization. However, the 
transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd significantly decreased to 40%, 
30%, and 15% after treating the cells with CLC respectively (p<0.0001). Upon treating the cells 
with CCD, the drug prevented the polymerization of actin filaments leading to their 
destabilization. The cellular uptake of NtAd was unaffected, while that of FlAd and PLL-g-PEG-
FlAd significantly decreased to 45% and 65% (p<0.05), respectively. Regarding the virus/hybrid 
vector ability to deliver genes into the nucleus after actin filaments destabilization by CCD. We 
observed a decrease in the transduction efficiency of NtAd, FlAd, and PLL-g-PEG-FlAd by 35% 
(p<0.001), 45% (p<0.0001) and 30% (p<0.01), respectively. 
We studied the effect of microtubule disruption or actin filament depolarization on the 
cellular uptake and the transduction efficiency of the hybrid vector in NIH 3T3 cells as well. The 
cellular uptake of the hybrid vector was unaffected upon treatment with either CLC or CCD 
(Figure 4.14A). The transduction efficiency of PLL-g-PEG-FlAd significantly decreased after 
treating cells with CLC, to 62% (p<0.001) (Figure 4.14B). The same effect was seen upon 
disrupting the actin microfilaments with CCD, where the transduction efficiency of PLL-g-PEG-
FlAd decreased to 40% (p<0.0001). In contrast, the transduction efficiency of NtAd was not 
affected by either drug inhibitors.  
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Figure 4.3: A) Cellular uptake and B) transduction efficiency of NtAd, and PLL15-30-g25%-PEG0.5-
FlAd in the presence of drug inhibitors in HEK 293. Y-axis – Normalized values of the virus or 
hybrid vector normalized to the same uptake for untreated cells. X-axis – Drugs at optimal 




Figure 4.3: A) Cellular uptake and B) transduction efficiency of NtAd, and PLL4-15-g5%-PEG5-
FlAd in the presence of drug inhibitors in NIH 3T3. Y-axis – Normalized values of the virus or 
hybrid vector normalized to the same uptake for untreated cells. X-axis – Drugs at optimal 






























































































































Accounting for the effects of intracellular trafficking is of critical importance to ensure 
that engineered viral vectors can induce good gene expression in target cells.  In our study, the 
adenovirus fiber protein was removed to eliminate the dependency of the virus on the CAR, 
which led to the virus losing its ability to bind to cells. We replaced the function of the fiber with 
PLL-g-PEG and wanted to study how the properties of this synthetic coating would affect the 
gene delivery trafficking pathway. By comparing the hybrid vector performance to the native 
virus, we can determine the important steps in the gene delivery process and design better 
materials accordingly. Cellular trafficking experiments were based on quantifying the virus via a 
qPCR technique, which was designed to amplify the adenoviral E2 gene. Since the expression of 
Ad E2 gene starts to increase between 12 and 13 hours after infection [297], quantifying the 
viruses within the first few hours guaranteed that the measured viruses were the experimentally 
added viruses to the cell and not any of their progeny.  
The first step to Ad transduction is the binding of the virus to the cell surface followed by 
internalization. We studied the binding and internalization of PLL-g-PEG-FlAd and compared it 
to NtAd and FlAd in CAR-positive (HEK 293) and CAR-negative (NIH 3T3) cells. FlAd had a 
poor binding ability to HEK 293 cells because of the absence of the key binding pathway which 
is the interaction of the knob domain of the fiber protein and CAR. Upon modifying FlAd with 
PLL-g-PEG copolymer, the ability of the hybrid vector to bind to the cell was partially restored. 
The affinity of NtAd to CAR is much higher compared to the lower electrostatic attraction 
between the cationic hybrid vectors and the anionic cell membrane[298]. All NtAd bound to cells 
were internalized while only approximately two thirds of hybrid vectors that bound to cells were 
internalized. This might explain the observed lower transduction efficiency of the hybrid vector 
compared to NtAd. The results infer that internalization of the hybrid vector is a bottleneck 
towards achieving better gene delivery in CAR-positive cell. In contrast, the hybrid vector 
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showed high binding levels in CAR-negative cells that were 55-fold higher compared to NtAd 
and FlAd. Both NtAd and FlAd virus lacked an efficient way to bind to the cell membrane while 
the hybrid vector used electrostatic attraction to mediate good binding to CAR-negative cells. All 
the NtAd, FlAd, and hybrid vectors achieved high levels of internalization (> 80% of the 
respective virus/hybrid vector bound to the cells). These results suggest that if we were able to 
design vectors with higher binding capacity to CAR-negative cells, we would have a greater 
number of internalized viruses and thus better gene delivery efficiency. 
HSPGs are glycoproteins with a heparan sulfate moiety and are ubiquitously expressed 
by most mammalian cell types [299]. HSPGs can serve as a co-receptor for Ad thereby increasing 
the concentration of virus at the cell surface and leading to more efficient interaction with CAR 
[281, 282]. HSPGs possess an overall negative charge and can interact electrostatically with 
cationic viral capsid proteins [300]. We hypothesized that our cationic hybrid vectors would 
attach to the cells via electrostatic interactions with HSPGs. Since heparin has a structure that is 
similar to heparan sulfate [301], heparin acts as a competitive inhibitor and decreases the hybrid 
vector electrostatic interactions with heparan sulfate. We demonstrated here that the addition of 
heparin immediately before transduction with hybrid vectors reduced the levels of gene delivery. 
This suggests that binding to heparan sulfate may play a role in the transduction of our hybrid 
vectors in the absence of higher affinity interactions like CAR binding.  
Next, we studied the endocytic pathways in CAR-positive (HEK 293) cells that the 
hybrid vector uses compared to the native virus. Cellular entry of NtAd was primarily based on 
clathrin-mediated endocytosis as indicated by the reduction in cellular uptake and transduction 
efficiency in the presence of CPZ (Figure 9A and B). Although not as impactful as CPZ, AMD 
also reduced the uptake and transduction of NtAd proving that macropinocytosis is an additional 
route that the virus uses to enter cells. Our findings are consistent with other studies that state that 
Ad uses macropinocytosis in addition to clathrin-mediated endocytosis for cell entry [302, 303]. 
While NtAd used clathrin-mediated endocytosis more than macropinocytosis; FlAd used both 
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pathways almost equally to enter the cells. This observed effect might be attributed to the fact that 
FlAd lacks the fiber-CAR interaction that prompts clathrin mediated endocytosis and instead 
binds to αv integrin which triggers macropinocytosis [304]. Our study shows that the virus fiber 
is not required for viral entry and is supported by previous findings reporting that the shedding 
the fiber and viral entry via endocytosis appear to be independent events during adenovirus cell 
entry [305].The hybrid vector entered the cell via clathrin-mediated endocytosis and 
macropinocytosis equally as shown in Figure 4.9A and B. Several studies have reported that 
cellular internalization of cationic polyplexes (ex: PLL-DNA) was through clathrin-dependent 
and independent endocytosis and macropinocytosis pathways [267, 270, 306]. 
After endocytosis, we studied endolysosomal escape and the cytoplasmic transport using 
BAF and CLC, respectively. At first, we evaluated the effect of each drug on the cellular uptake 
of hybrid vectors to confirm that the decrease in transduction efficiency was due to impaired 
endolysosomal escape or cytoplasmic transport and not by the inhibition of cellular uptake. 
Neither drug showed a significant effect on the cellular uptake of the virus or the hybrid vector 
(Figure 4.11A and Figure 4.13A). 
Endosomal escape is known as a possible rate-limiting step and may explain the 
differences in gene expression. There has been some debate on whether or not acidification of 
endosomes (pH 4.6 – 6.0) is necessary for infection by NtAd [305], with some arguments stating 
that acidification triggers conformational changes that lead to release of the membrane lytic 
protein VI [307] and others arguing that different mechanical stresses between the virus and 
integrins in the cell plasma membrane  during cellular entry may initiate disassembly of the virus 
particle even before it reaches the early endosome to help release protein VI [308]. Regardless of 
what leads to release of protein VI, once the protein is released a membrane lytic region is 
inserted into the endosomal membrane imparting partial membrane rupture and release of the 
virus into the host cell cytoplasm [251].  
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Our results suggest that both mechanisms for release of protein VI may be relevant. 
Blocking acidification of endosomes appears to have some effect on the performance of NtAd 
with a 35% decrease in its transduction efficiency as shown in Figure 4.11B. Although blocking 
acidification negatively impacted the performance of the virus, it did not completely eliminate its 
ability to infect. This may be because the virus has undergone conformational changes through 
mechanical stresses created by the virus binding to integrins that leads to some exposure of 
protein VI and endosomal escape of the virus [309]. FlAd is expected to also be sensitive to 
blocking acidification of endosomes since the fiber is not present to undergo a pH-induced 
conformation transformation that leads to release of protein VI. Further, the absence of the fiber 
protein will greatly reduce the mechanical stresses that would normally occur as a result of fiber 
protein binding to CAR and integrin receptors[305]. Consistent with this was our observation that 
blocking acidification of endosomes reduced transduction efficiency of FlAd by 70%. Our results 
show that the Ad fiber protein plays an important role in Ad disassembly and escape from the 
endolysosomal pathway and that its role requires acidification of the endosome, consistent with 
the mechanistic studies mentioned above. 
Interestingly, the addition of PLL-g-PEG to FlAd appears to offset the impact of BAF on 
a fiberless virus particle. Blocking acidification still reduces the transduction efficiency of the 
hybrid vector but only by ~35% not the ~70% experienced by the fiberless virus. Different 
hypotheses have been postulated to explain how cationic polymers such as PLL-g-PEG are able 
to escape from endosomes [41]. We attribute the endosomal escape of hybrid vectors to either of 
the two following theories. First, the cationic hybrid vector might have interacted with the 
endosomal membrane leading to membrane damage/permeability and nanoscale hole formation 
[268, 271, 272]. Banaszak Holl and his group investigated a broad range of cationic polymers 
including PLL and identified membrane damages like membrane thinning and transient 
membrane hole formation which lead to leakage of nanosized cargo [310]. Second, the free 
cationic PLL-g-PEG chains might have intercalated into the endosomal membrane to cause 
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defects in the lipid layer and leakage of the nanosized vectors. Previous studies have reported the 
effect of the free polymer-mediated membrane permeability in endosomal escape [311]. 
After endosomal escape, the virus is released into the cytosol to be transported to the 
nucleus. There are two main types of cytoskeletal polymers, actin filaments and microtubules,  
that are responsible for transport of intracellular cargo [312]. CLC disrupted microtubules without 
significantly affecting the cellular uptake of NtAd or hybrid vectors (Figure 4.13A). However, the 
transduction efficiency of NtAd decreased by 60%, while that of the hybrid vector transduction 
further decreased by 85% compared to untreated cells (Figure 4.13 B). Previous studies showed 
that drug inhibitors like CLC that disrupt microtubules had no effect on cell entry but prevented 
viral translocation to the nucleus [313]. Based on our data, we can deduce that the hybrid vector 
is more highly dependent on microtubules as a cytosolic transport mechanism than NtAd. 
Actin microfilaments are the other cytoskeletal protein polymer that were studied.  Actin 
microfilaments are present throughout the entire cytosol, but the highest concentration forms a 
network of actin microfilaments directly beneath the plasma membrane (i.e., actin cortex). The 
actin cortex plays a role in endocytosis of particles into cells as well as provide mechanical 
strength to cells grown in cell culture [314]. Actin filaments mediate various intracellular 
transport processes as well as assist in genome replication inside the nucleus [315].  
CCD is a drug that prevents the polymerization of actin filaments affecting adenovirus 
entry and infection [250]. The role of CCD in cellular uptake is debatable.  Several studies have 
reported that early endocytic events are at least partially inhibited by CCD [316, 317]; others 
reported no effect on receptor-mediated endocytosis [318, 319] with no obligatory role in 
endocytic vesicle formation in cultured mammalian cells [320]. Because of the potential dual 
roles of actin in both cellular uptake and cellular transport its necessary to understand how CCD 
affects both of these aspects of the transduction process.   
Treating cells with CCD increased the uptake of NtAd (Figure 4.13A), however, it 
decreased uptake of both FlAd and PLL-g-PEG-FlAd. This effect can be explained based on the 
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following : a) electrostatic attraction  between FlAd or hybrid vectors and the cell membrane is 
weaker than NtAd-CAR binding, b) HEK 293 cells can round up and lose cell-cell contacts as a 
response to CCD action [321]. Therefore, cell rounding might have caused more NtAd to be 
uptaken. In contrast, the electrostatic attraction between FlAd/hybrid vector and the cell 
membrane might has been compromised upon cell rounding leading to the lower uptake observed 
upon CCD addition. We did not observe an increase in cellular uptake of NtAd in NIH 3T3 cells 
as observed in HEK 293 cells (Figure 4.14A) .Because no cell rounding was observed upon CCD 
treatment owing to the rigidity of the cell membrane of NIH 3T3 compared to HEK 293 cells 
[216]. 
Although cellular uptake of NtAd was not affected by CCD, the transduction efficiency 
of NtAd decreased by 25% (Figure 4.13B). Ad is known to primarily use microtubules for 
cytoplasmic transport, which might cause one to question why disruption of actin microfilaments 
would hinder intracellular transport of the virus.  Whether or not actin microfilaments play a role 
in virus transport, however, remains uncertain.  In fact, some researchers have found that Ad can 
interact with different cytoskeletal systems and utilize both microtubule-dependent and 
microtubule-independent mechanisms [322, 323]. Previous studies have also reported that Ad 
infection not only depends on actin dynamics for transport, but nuclear actin polymerization is 
also needed for efficient viral gene transcription [315]. Consequently, disruption of actin 
microfilaments by CCD may have decreased intracellular transport of the virus or compromised 
reporter gene expression or some combination of these two mechanisms. 
Treatment with CCD reduced the transduction efficiency of PLL-g-PEG FlAd to levels 
similar to the NtAd. This reduction in gene delivery efficiency is likely to be related to cellular 
uptake of the hybrid vector. As seen in Figure 4.13A, CCD decreased uptake of the hybrid vector 
by about 65%.  Reporter gene expression from the hybrid vector also decreased by about 55% 
when cells were treated with CCD.  Since reporter gene expression is ultimately reliant on both 
uptake and intracellular transport, we would expect gene expression to be reduced by more than 
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55% if CCD were further affecting cellular transport in addition to cellular uptake.  Consequently, 
the hybrid vector does not appear to use actin microfilaments for intracellular transport and 
instead relies entirely on microtubules for transport through the cell cytosol.  
Based on the intracellular trafficking of the hybrid vector in CAR-positive cells, the 
hybrid vector was internalized via clathrin-mediated endocytosis and macropinocytosis; the levels 
of internalization of hybrid vectors into the cells, however, were lower compared to the native 
virus. Subsequently, despite of the removal of the fibers that played a role in virus release from 
the endosomes, the copolymer coating helped the hybrid vectors to achieve similar transduction 
efficiencies as the native virus upon inhibiting acidification of endosomes. Lastly, the hybrid 
vector relied primarily on microtubules to reach the nucleus and did not show good transduction 
upon microtubule disruption. We can conclude that internalization and cytosolic transport of 
hybrid vectors appear to be important steps in transducing CAR-positive cells that subsequently 
lead to low levels of transduction efficiency relative to NtAd. 
In addition to studying how the hybrid vector transduces CAR-positive cells, we were 
also interested to know how the vector transduces cells that the native virus would not normally 
be capable of infecting.  For this purpose, we studied the hybrid vector transduction of CAR-
negative (NIH 3T3) cells. As different cells vary in their morphology and functions, it would be 
surprising if all cells interacted with viral vectors in identical manners. The internalization 
pathways were studied using the same drug inhibitors.  CPZ and AMD significantly reduced the 
cellular uptake(Figure 4.10A)) and the transduction efficiency (Figure 4.10B) of NtAd in NIH 
3T3 cells. This indicated that NtAd entered NIH 3T3 cells via clathrin-mediated endocytosis and 
macropinocytosis. The hybrid vector entered the cells via clathrin- and caveolae- mediated 
endocytosis as the cellular uptake was reduced by 50% and 35% upon using CPZ and GST, 
respectively. The transduction efficiency results of the hybrid vector supported the same findings 
where we observed a 45% and a 25% decrease in the transduction efficiency of the hybrid vector 
after inhibition with CPZ and GST, respectively. Endocytosis depends on different properties, 
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such as the polymer molecular weight, type of polymer used to create the nanoparticle, and cell 
type. Caveolae are preferentially involved in the internalization of larger particles, i.e. with 
diameters exceeding 200 nm [263]. Our hybrid vectors transducing NIH 3T3 cells have a particle 
size of 270 nm and thus have the potential to be endocytosed via a caveolae-mediated pathway. 
Moreover, caveolae are not common to all eukaryotic cells but are abundantly present in many 
cell types including fibroblasts and adipocytes [324]. Previous studies have also shown that 
modification of the adenoviral tropism can induce deficient clathrin-mediated endocytosis of the 
viral particles, which can infect refractory CAR-negative cells through a non-clathrin-mediated 
endocytosis pathway [325].  
Next, we studied the endosomal escape of hybrid vectors. Cellular uptake of NtAd and 
PLL-g-PEG-FlAd after inhibition with BAF was unaffected (Figure 4.12A). This is not surprising 
as we expect the drug to play no role in the uptake of the virus or the hybrid vector.  The 
transduction efficiency of the NtAd and the hybrid vector was significantly reduced after treating 
cells with BAF (Figure 4.12 B). Inhibition of endosomal acidification affected the gene 
expression of NtAd in NIH 3T3 similar to how it did in HEK 293 cells. The fact that BAF 
reduces transduction efficiency of the hybrid vector by ~70% seems to suggest that the vector 
primarily relied on pH-induced conformational changes that led to exposure of protein VI. The 
native virus, however, was not impacted as severely as the hybrid vector. This might be due to the 
native virus have a better chance for protein VI exposure compared to the polymer-coated hybrid 
vector. There are several possible explanations for how the hybrid vector was able to escape the 
endosomal pathway and transduce at all in the presence of BAF.  One potential explanation may 
be that mechanical stresses were created that led to exposure of protein VI in a pH-independent 
manner. These mechanical stresses may have been induced by the polymer or maybe by integrin 
binding.  Another possible explanation is that transduction resulted from the portion of the vector 
that entered through the caveolae-mediated pathway.  This pathway is known to avoid 
acidification and release endosomal contents through a process that involves merging with the 
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golgi and endoplasmic reticulum [326]. A third possible explanation is that the PLL polymer 
facilitated release of the virus in a pH-independent manner. The endosomal escape of hybrid 
vectors was difeerent in between HEK 293 and NIH 3T3 cells. Hybrid vectors transducing NIH 
3T3 were prepared with a PLL of lower Mwt (4-15 kDa) and were less cationic (7.5 mV) 
compared to vectors used in HEK 293 cells and prepared with PLL of higher Mwt (15-30 kDa). 
This resulted in a better transduction efficiency from hybrid vectors in HEK 293 cells compared 
to NIH 3T3 cells upon inhibiting acidification by BAF. Previous researchers have shown that 
different degrees of membrane damages were influenced by the polymer molecular weight, 
charge density, and concentration [204, 272, 327].  
After release into the cytoplasm, we studied the cellular uptake of NtAd and PLL-g-PEG-
FlAd after inhibition with CLC and CCD, which was not significantly affected (Figure 4.14A). 
This indicates that both drugs played no role in cellular entry in NIH 3T3 cells. The transduction 
efficiency of NtAd was not impacted significantly by disruption of actin microfilaments by CCD 
but decreased upon microtubule disruption by CLC (Figure 4.14B). The hybrid vector used both 
microtubules and actin microfilaments for cytosolic transport to the nucleus as their transduction 
efficiency was reduced by 36% and 62% after treating the cells with CLC and CCD, respectively 
(Figure 4.14B). The ability of the hybrid vector to use both actin microfilaments and microtubulin 
in cytoplasmic transport in CAR-negative cells might help explain the overall improved 
transduction efficiency of the hybrid vector relative to NtAd. 
Based on the intracellular trafficking studies of hybrid vectors in CAR-negative cells. 
Hybrid vectors showed higher binding levels compared to NtAd in CAR-negative (NIH 3T3). 
Nearly all of the bound NtAd and hybrid vector were internalized, and both vectors used more 
than one pathway to enter the cell. The hybrid vector was internalized via clathrin-mediated 
endocytosis and caveola-mediated endocytosis. Although acidification of the endosomal network 
is more important for the hybrid vector, it is not clear how well the virus escapes the endosomal 
network under normal conditions. Next, hybrid vectors used more than one pathway for 
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cytoplasmic transport to reach the nucleus including microtubules and actin microfilaments. 
However, there is only a 10-fold improvement in transduction efficiency, while we achieved 55-
fold increase in cellular attachment. These results indicate that the hybrid vector must perform 
better compared to the native virus when it comes to attachment but poorly when it comes to 
either endosomal escape, intracellular trafficking, or nuclear entry. 
Table 4.3: Summary of uptake mechanisms and trafficking pathways of NtAd and PLL-g-PEG-
FlAd hybrid vector in CAR-positive and CAR-negative cells. 







Binding to cell +++ ++ - ++ 















Clathrin +++ ++ +++ ++ 
Caveolae    + 
Macropinocytosis + ++ + - 
Role of pH on 
Endosomal Escape 














 Microtubule +++ ++ +++ ++ 
Actin Filaments + +  ++ 
4.5 CONCLUSION 
Hybrid vectors are promising vehicles for delivering therapeutic genes because of their 
relatively safe profile compared to their viral counterparts. However, the transduction efficiency 
of hybrid vectors is less than satisfactory for clinical purposes. Vector-mediated transduction 
efficiency reflects the sum of the vector binding, internalizing, and undergoing intracellular 
trafficking. An ideal gene delivery vector should facilitate cellular uptake, promote endosomal 
escape, and release transgenes within the nucleus 
In our study, the adenovirus fiber protein was removed, and its function replaced via PLL-g-PEG 
copolymer. The surface modification with a cationic copolymer allowed for electrostatic 
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association with anionic heparan sulfate proteoglycan receptors on the cell membrane, which 
eliminated the dependence on CAR and facilitated the use of an alternative pathway for cell 
binding. In CAR-positive cells, including design features that improve internalization and 
cytosolic transport would result in hybrid vectors that have potential to better transduce these 
cells. In CAR-negative cells, designing a hybrid vector with better binding is a key mechanism to 
enhance transduction of these cells. The stepwise approach in replacing viral vector proteins with 
synthetic components would enable the development of a completely non-viral vector that 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
Adenovirus is the most commonly used viral vector in gene therapy clinical trials. 
While this viral vector is highly efficient and can transduce a wide profile of cells 
including dividing and non-dividing cells as well as accommodating large transgenes up to 
8.5 kbp, it suffers from many issues such as broad tropism making it difficult for specific 
targeting for different cell lines and high immunogenicity. These disadvantages are 
particularly associated with the presence of the fiber protein on the capsid of the 
adenovirus. The fiber protein, however, is solely responsible for binding to target cells 
having coxsackie adenovirus receptor (CAR) without which the adenoviral particle is 
ineffective. In this dissertation, we explored the possibility of removing the fiber protein 
and replacing it with poly-l-lysing grafted poly-ethylene glycol (PLL-g-PEG) copolymer to 
mediate effective transduction by effectively performing the functions of the native fiber 
protein. 
This replacement of the fiber protein would also provide certain advantages of 
synthetic agents with respect to clinical implementation of human gene therapy while still 
maintaining the good transduction capabilities of adenovirus thereby leading to the design of 
a novel hybrid gene delivery vector. 
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As per our results reported in this document, the function of the fiber of adenovirus in 
mediating good transduction efficiency was replaced by the physical modification of the virus with 
PLL-g-PEG copolymer. To achieve small particle size, high cationic charge and good transduction 
efficiency, there should be a balance between PLL Mwt, PEG Mwt, DOP, and the amount of 
copolymer/virus. Hybrid vectors prepared with high PLL Mwt ( up to 30 kDa) is better to be 
combined with either low PEG Mwt (0.5 or 2 kDa) at high degree of PEGylation (25%) or with high 
PEG Mwt (5 kDa) at low degree of PEGylation (5%) to achieve a good balance between the particle 
size and the exposed cationic charge on the PLL chain for better transduction efficiency. Low Mwt 
PEG (5kDa) have the advantage of reacting with high Mwt PEG (5kDa) at high degree of 
PEGylation and still resulting in small particle sized hybrid vectors with high transduction 
efficiency. Multifactor testing via statistical model design (Design of experiment generated a D-
optimal design) allowed us to optimize hybrid vectors to achieve the highest transduction efficiency 
in CAR-positive (HEK 293) and CAR- negative (NIH 3T3) cells. PLL-g-PEG-FLAd hybrid vectors 
were more efficient at transducing CAR-positive (HEK293) cells in vitro with 3.5-fold increase 
compared to FlAd. Those hybrid vectors restored 85% of the lost infectivity due to fiber removal.  
PLL-g-PEG-FLAd hybrid vectors were also more efficient at transducing CAR-negative (NIH 3T3) 
cells in vitro with 10-fold increase compared to FlAd that was refractory to transduce the cells. 
Hybrid vectors showed good gene expression in a CAR-independent way. Since results cannot be 
generalized to every cell type, a design of experiment is recommended as a future direction to 
achieve the required responses in terms of particle size, zeta potential and transduction efficiency in 
the cells of interest. This design can be used as a guide towards that with some recommendations 
like excluding high PLL Mwt as 30-70 kDa and extending PEG Mwt to higher molecular weights. 
Different PEG Mwt can be aslo tested in vivo to correlate the results with in vitro results for better 
optimization.  
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Optimized hybrid vectors were tested for their cytotoxicity, serum stability, innate 
immunogenicity, and transduction of various CAR- negative cells. PLL-g-PEG proved to be highly 
biocompatible as compared to PEI and PLL exhibiting much lower toxicity in HEK293 and NIH 
3T3 cells. Hybrid vectors have also induced a weaker innate immune response as we have seen 
lower production of proinflammatory cytokine. Hybrid vectors exhibited better serum resistance 
compared to NtAd and FlAd, as they showed better transduction efficiencies in both HEK 293 and 
NIH 3T3 cells in different serum concentrations up to 50%. We have shown that excellent in vitro 
transduction efficiency can be potentially achieved using hybrid vectors designed to transduce 
CAR- negative cells. These hybrid vectors showed high transduction efficiency of 20- fold and 4-
fold increase compared to FlAd in CAR low cells as MCF-7 cancer cells and in CAR-negative cells 
as CHO, respectively. The future directions for the design of adenoviral based hybrid vectors should 
be directed towards optimization of the morphology of vectors through optimal combination of 
PLL, PEG at an optimal DOP and concentration to achieve highest transduction efficiency in MCF-
7 cells. Breast cancer cells are recommended as a target for our hybrid vectors. This can be achieved 
through either of the following two approaches or combining both: (1) Further optimization of our 
hybrid vectors to better transduce breast cancer cells to be used as an intratumoral injection into 
breast cancer cells, or (2) Conjugating a target ligand to hybrid vectors to either target epidermal 
growth factor receptor (EGFR) or  HER2 receptor to be systemically administrated to target breast 
cancer cells. The resulting hybrid vectors can be potentially used for breast cancer gene therapy 
following appropriate characterization of the biodistribution and efficacy of these hybrid vectors in 
vivo. 
The cellular uptake and intracellular trafficking of hybrid vectors explained their attachment, 
internalization, endosomal escape and cytosolic transport to the cell nucleus. The surface modification 
with a cationic copolymer as PLL-g-PEG eliminated the dependence on CAR and facilitated electrostatic 
association with anionic heparan sulfate proteoglycan receptors on the cell membrane for cellular 
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attachment. In CAR-positive cells, the lower internalization levels achieved by hybrid vectors compared 
to NtAd is a major cause of the lower performance of hybrid vectors and restoring only 85% of the 
infectivity lost due to fiber removal. In CAR-negative cells, the superiority of the binding levels 
compared to NtAd explains the better performance of hybrid vectors in transducing those cells. The 
intracellular trafficking significantly differed based on the type of cells as well as the composition of 
PLL-g-PEG used for FlAd. NtAd used clathrin-mediated endocytosis and macropinocytosis to enter 
CAR-positive and CAR-negative cells, as known in literature. In contrast, hybrid vectors used the same 
pathways as NtAD to enter CAR-positive, whereas they used clathrin- and caveola-mediated endocytosis 
to enter CAR-negative cells. After being endocytosed, surface modification of FlAd with PLL-g-PEG 
restored the endosomal escape efficiency to the same level of NtAd in CAR-positive cells. In contrast, 
this modification failed to help vectors to escape from endosomes in CAR-negative cells. The endosomal 
escape of hybrid vectors showed high dependence on pH change (acidification) in CAR-positive 
compared to CAR-negative cells. After release into cytosol, hybrid vectors relied on microtubules in 
CAR-positive cells, whereas hybrid vectors were flexible to use microtubules or microfilaments for 
transport across the cytosol. Future directions of designing a hybrid vector with better binding is a key 
mechanism to enhance transduction of CAR-negative cells. This enhancement can be achieved via 
including ligands to interact with either nonspecific cell receptors as saccharide receptors or with specific 
receptors according to targeted cells. In addition, including design features that improve endosomal 
escape of hybrid vectors in CAR-negative cells is recommended like lactosylated PLL, histidine modified 
PLL or bioreducible PLL derivatives or incorporation of proteins as GALA or KALA into the design. If 
CAR-positive cells are a target of future studies, it is recommended to including design features that 
improve internalization like cell penetrating peptides or lipid enhancers as phosphatidylcholine, 
phosphatidylserine, or sphingomyelins. Moreover, better binding of hybrid vectors to dynein motor 
proteins would enhance transport along microtubules in CAR-positive cells.  
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We wholly expect that the design of hybrid vectors (CAR-negative design) can be extended 
towards treating cancer cells. Hybrid vectors can benefit from the fact that endosomes of cancer cells 
have lower pH to help better escape and release of vectors into the cytosol. Also, the ability of using 
different cytosolic transport mechanisms can be an advantage in cancer cells when microtubule 
function and activity changes. Future studies should be targeted towards design of therapeutic hybrid 
vectors that have a clinically useful target gene or an RNAi construct for cancer gene therapy.  
Finally, future studies may include the effect of fiber removal and surface modification on 
transduction of hepatic cells and inducing liver toxicity as we expect both effects to decrease.  
Therefore, improvement of hybrid vector efficiency would result in lower dose administration which 
decreases accompanying adverse effects. A balance between efficacy and toxicity of hybrid vectors 
is very essential in clinical gene therapy. Furthermore, studying the suitable route of administration 
for these hybrid vectors wither by local administration or systemic administration is important to 
reduce immunotoxicity, inflammatory response and systemic effects. Finally, the ultimate goal 
should be replacing viral vector parts with synthetic components to develop a non-viral vector that 
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I. Grafting ratio calculation and 1HNMR 
The grafting ratio of PEG onto PLL was determined using 1H NMR spectroscopy. The number of 
PEG chains grafted onto the PLL was calculated by integrating the peaks in the PLL-g-PEG 
NMR spectrum that correspond to protons of the PLL (-CH- at 4.3 ppm) and PEG (-CH2CH2- at 
3.7 ppm) portions of the copolymer. First, the number protons per mole of PEG were calculated 
by using the PEG molecular weight (5kDa) (Equation 1). Next, the average number of protons 
per mole of PLL was calculated by using the molecular weight of the PLL polymers (22,500 Da) 
(Equation 2). The relative number of moles of PEG and PLL were calculated by taking the 
quotient of the polymer peak area and the number of protons per mole of the polymer (Equations 
3 and 4). Once the relative number of moles of each polymer was determined, the grafting ratio 
was calculated by taking the quotient of the relative number of moles of PEG and the relative 
number of moles of PLL (Equation 5). The calculation used to determine the grafting ratio and a 
sample 1HNMR spectrum are included: 









  1. 













𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑜𝑙𝑒𝑠 𝑃𝐸𝐺 =
𝐴𝑟𝑒𝑎𝑃𝐸𝐺
𝑁𝑃𝐸𝐺
  3. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑜𝑙𝑒𝑠 𝑃𝐿𝐿 =
𝐴𝑟𝑒𝑎𝑃𝐿𝐿
𝑁𝑃𝐿𝐿
  4. 
     𝐺𝑟𝑎𝑓𝑡𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 =
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑃𝐸𝐺
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑃𝐿𝐿
                                                                5. 






II. Determination of fold difference in cellular uptake of NtAd, FlAd or hybrid vectors after 
treatment with drug inhibitors using Livak method (ΔΔCt) 
It is used as a relative quantitation method to compare the efficiency of expression of gene of a test 
compared to a control. 
Steps: 
1- Normalize Ct (target gene) to Ct (reference gene) 
2- Normalize ΔCt of test sample to Δ Ct of calibrator. 
3- Calculate fold difference.  
Example: 
 
1- Normalize Ct (target gene) to Ct (reference gene) 
ΔCt (untreated) = 29.33 – 20.3 = 9.03 
ΔCt (treated) = 31.11 – 23.16 = 7.95 
2- Normalize Δ Ct of test sample to ΔCt of calibrator. 
ΔΔ Ct = ΔCt (untreated) - ΔCt (treated) = 9.03 – 7.95 = 1.08 
 
3- Calculate fold difference in gene expression. 
2-ΔΔ Ct = Normalized gene expression  
2-(1.08) = 0.47 
 
Treated cells express gene at 0.47-fold lower than control cells. 
  
Sample Gene 
 Target Reference 
Control Ct (Target, control) Ct (reference, control) 
Test Ct (target, test) Ct (reference, test) 
Sample Gene 
 Target (E2) Reference (ACTB) 
Untreated 29.33 20.3 
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